#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Presumed Structural and Functional Neural Recovery after Long-Term Abstinence from Cocaine in Male Military Veterans Cumulative evidence suggests that cocaine use could alter the structure and function of different brain systems.
1-1	0-8	Presumed	_
1-2	9-19	Structural	_
1-3	20-23	and	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-4	24-34	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-5	35-41	Neural	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-6	42-50	Recovery	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-7	51-56	after	_
1-8	57-66	Long-Term	_
1-9	67-77	Abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
1-10	78-82	from	_
1-11	83-90	Cocaine	_
1-12	91-93	in	_
1-13	94-98	Male	_
1-14	99-107	Military	_
1-15	108-116	Veterans	_
1-16	117-127	Cumulative	_
1-17	128-136	evidence	_
1-18	137-145	suggests	_
1-19	146-150	that	_
1-20	151-158	cocaine	_
1-21	159-162	use	_
1-22	163-168	could	_
1-23	169-174	alter	_
1-24	175-178	the	_
1-25	179-188	structure	_
1-26	189-192	and	_
1-27	193-201	function	_
1-28	202-204	of	_
1-29	205-214	different	_
1-30	215-220	brain	_
1-31	221-228	systems	_
1-32	229-230	.	_

Text=However, the extent to which the altered brain structure and function possibly recover over time after cocaine abstinence remains less clear.
2-1	231-238	However	_
2-2	239-240	,	_
2-3	241-244	the	_
2-4	245-251	extent	_
2-5	252-254	to	_
2-6	255-260	which	_
2-7	261-264	the	_
2-8	265-272	altered	_
2-9	273-278	brain	_
2-10	279-288	structure	_
2-11	289-292	and	_
2-12	293-301	function	_
2-13	302-310	possibly	_
2-14	311-318	recover	_
2-15	319-323	over	_
2-16	324-328	time	_
2-17	329-334	after	_
2-18	335-342	cocaine	_
2-19	343-353	abstinence	_
2-20	354-361	remains	_
2-21	362-366	less	_
2-22	367-372	clear	_
2-23	373-374	.	_

Text=The present study examines 39 male military veterans with different stages of cocaine addiction and long-term abstinence (from 1 year up to 30 years) and evaluates plausible changes in brain structure and function of specific brain regions that sub-serve addictions.
3-1	375-378	The	_
3-2	379-386	present	_
3-3	387-392	study	_
3-4	393-401	examines	_
3-5	402-404	39	_
3-6	405-409	male	_
3-7	410-418	military	_
3-8	419-427	veterans	_
3-9	428-432	with	_
3-10	433-442	different	_
3-11	443-449	stages	_
3-12	450-452	of	_
3-13	453-460	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
3-14	461-470	addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
3-15	471-474	and	_
3-16	475-484	long-term	_
3-17	485-495	abstinence	_
3-18	496-497	(	_
3-19	498-502	from	_
3-20	503-504	1	_
3-21	505-509	year	_
3-22	510-512	up	_
3-23	513-515	to	_
3-24	516-518	30	_
3-25	519-524	years	_
3-26	525-526	)	_
3-27	527-530	and	_
3-28	531-540	evaluates	_
3-29	541-550	plausible	_
3-30	551-558	changes	_
3-31	559-561	in	_
3-32	562-567	brain	_
3-33	568-577	structure	_
3-34	578-581	and	_
3-35	582-590	function	_
3-36	591-593	of	_
3-37	594-602	specific	_
3-38	603-608	brain	_
3-39	609-616	regions	_
3-40	617-621	that	_
3-41	622-631	sub-serve	_
3-42	632-642	addictions	_
3-43	643-644	.	_

Text=These include the striatum that is involved in cocaine reward; the lateral prefrontal cortex (especially the dorsolateral PFC) that plays a major role in inhibitory control; the insula, which has been implicated in craving; and the medial orbitofrontal (OFC) and ventromedial prefrontal cortex (VMPFC) shown to play key roles in foresight and decision-making.
4-1	645-650	These	_
4-2	651-658	include	_
4-3	659-662	the	_
4-4	663-671	striatum	_
4-5	672-676	that	_
4-6	677-679	is	_
4-7	680-688	involved	_
4-8	689-691	in	_
4-9	692-699	cocaine	_
4-10	700-706	reward	_
4-11	707-708	;	_
4-12	709-712	the	_
4-13	713-720	lateral	_
4-14	721-731	prefrontal	_
4-15	732-738	cortex	_
4-16	739-740	(	_
4-17	741-751	especially	_
4-18	752-755	the	_
4-19	756-768	dorsolateral	_
4-20	769-772	PFC	_
4-21	773-774	)	_
4-22	775-779	that	_
4-23	780-785	plays	_
4-24	786-787	a	_
4-25	788-793	major	_
4-26	794-798	role	_
4-27	799-801	in	_
4-28	802-812	inhibitory	_
4-29	813-820	control	_
4-30	821-822	;	_
4-31	823-826	the	_
4-32	827-833	insula	_
4-33	834-835	,	_
4-34	836-841	which	_
4-35	842-845	has	_
4-36	846-850	been	_
4-37	851-861	implicated	_
4-38	862-864	in	_
4-39	865-872	craving	_
4-40	873-874	;	_
4-41	875-878	and	_
4-42	879-882	the	_
4-43	883-889	medial	_
4-44	890-903	orbitofrontal	_
4-45	904-905	(	_
4-46	906-909	OFC	_
4-47	910-911	)	_
4-48	912-915	and	_
4-49	916-928	ventromedial	_
4-50	929-939	prefrontal	_
4-51	940-946	cortex	_
4-52	947-948	(	_
4-53	949-954	VMPFC	_
4-54	955-956	)	_
4-55	957-962	shown	_
4-56	963-965	to	_
4-57	966-970	play	_
4-58	971-974	key	_
4-59	975-980	roles	_
4-60	981-983	in	_
4-61	984-993	foresight	_
4-62	994-997	and	_
4-63	998-1013	decision-making	_
4-64	1014-1015	.	_

Text=The results suggest that there are differences in both brain structure (gray matter volume, GMV) and function between cocaine USERS and CONTROLS, with USERS showing plausible relative strengthening in neural systems for processing reward and craving, and relative weakening in neural systems involved in inhibitory control and decision-making.
5-1	1016-1019	The	_
5-2	1020-1027	results	_
5-3	1028-1035	suggest	_
5-4	1036-1040	that	_
5-5	1041-1046	there	_
5-6	1047-1050	are	_
5-7	1051-1062	differences	_
5-8	1063-1065	in	_
5-9	1066-1070	both	_
5-10	1071-1076	brain	_
5-11	1077-1086	structure	_
5-12	1087-1088	(	_
5-13	1089-1093	gray	_
5-14	1094-1100	matter	_
5-15	1101-1107	volume	_
5-16	1108-1109	,	_
5-17	1110-1113	GMV	_
5-18	1114-1115	)	_
5-19	1116-1119	and	_
5-20	1120-1128	function	_
5-21	1129-1136	between	_
5-22	1137-1144	cocaine	_
5-23	1145-1150	USERS	_
5-24	1151-1154	and	_
5-25	1155-1163	CONTROLS	_
5-26	1164-1165	,	_
5-27	1166-1170	with	_
5-28	1171-1176	USERS	_
5-29	1177-1184	showing	_
5-30	1185-1194	plausible	_
5-31	1195-1203	relative	_
5-32	1204-1217	strengthening	_
5-33	1218-1220	in	_
5-34	1221-1227	neural	_
5-35	1228-1235	systems	_
5-36	1236-1239	for	_
5-37	1240-1250	processing	_
5-38	1251-1257	reward	_
5-39	1258-1261	and	_
5-40	1262-1269	craving	_
5-41	1270-1271	,	_
5-42	1272-1275	and	_
5-43	1276-1284	relative	_
5-44	1285-1294	weakening	_
5-45	1295-1297	in	_
5-46	1298-1304	neural	_
5-47	1305-1312	systems	_
5-48	1313-1321	involved	_
5-49	1322-1324	in	_
5-50	1325-1335	inhibitory	_
5-51	1336-1343	control	_
5-52	1344-1347	and	_
5-53	1348-1363	decision-making	_
5-54	1364-1365	.	_

Text=Examination of possible neural changes after abstinence suggests that presumed recovery occurs mostly in neural systems related to reward, craving, and inhibitory control, but to a lesser extent in neural systems related to decision-making.
6-1	1366-1377	Examination	_
6-2	1378-1380	of	_
6-3	1381-1389	possible	_
6-4	1390-1396	neural	_
6-5	1397-1404	changes	_
6-6	1405-1410	after	_
6-7	1411-1421	abstinence	_
6-8	1422-1430	suggests	_
6-9	1431-1435	that	_
6-10	1436-1444	presumed	_
6-11	1445-1453	recovery	_
6-12	1454-1460	occurs	_
6-13	1461-1467	mostly	_
6-14	1468-1470	in	_
6-15	1471-1477	neural	_
6-16	1478-1485	systems	_
6-17	1486-1493	related	_
6-18	1494-1496	to	_
6-19	1497-1503	reward	_
6-20	1504-1505	,	_
6-21	1506-1513	craving	_
6-22	1514-1515	,	_
6-23	1516-1519	and	_
6-24	1520-1530	inhibitory	_
6-25	1531-1538	control	_
6-26	1539-1540	,	_
6-27	1541-1544	but	_
6-28	1545-1547	to	_
6-29	1548-1549	a	_
6-30	1550-1556	lesser	_
6-31	1557-1563	extent	_
6-32	1564-1566	in	_
6-33	1567-1573	neural	_
6-34	1574-1581	systems	_
6-35	1582-1589	related	_
6-36	1590-1592	to	_
6-37	1593-1608	decision-making	_
6-38	1609-1610	.	_

Text=Given the limitations of the data in terms of a small sample size, as well as the lack of certainty about occasional use in the abstinent group, these results may be considered as preliminary.
7-1	1611-1616	Given	_
7-2	1617-1620	the	_
7-3	1621-1632	limitations	_
7-4	1633-1635	of	_
7-5	1636-1639	the	_
7-6	1640-1644	data	_
7-7	1645-1647	in	_
7-8	1648-1653	terms	_
7-9	1654-1656	of	_
7-10	1657-1658	a	_
7-11	1659-1664	small	_
7-12	1665-1671	sample	_
7-13	1672-1676	size	_
7-14	1677-1678	,	_
7-15	1679-1681	as	_
7-16	1682-1686	well	_
7-17	1687-1689	as	_
7-18	1690-1693	the	_
7-19	1694-1698	lack	_
7-20	1699-1701	of	_
7-21	1702-1711	certainty	_
7-22	1712-1717	about	_
7-23	1718-1728	occasional	_
7-24	1729-1732	use	_
7-25	1733-1735	in	_
7-26	1736-1739	the	_
7-27	1740-1749	abstinent	_
7-28	1750-1755	group	_
7-29	1756-1757	,	_
7-30	1758-1763	these	_
7-31	1764-1771	results	_
7-32	1772-1775	may	_
7-33	1776-1778	be	_
7-34	1779-1789	considered	_
7-35	1790-1792	as	_
7-36	1793-1804	preliminary	_
7-37	1805-1806	.	_

Text=However, they are compelling in that they suggest that male military veterans cocaine USERS are indefinitely at a higher risk for making lapses in judgment and decision-making leading to possible relapse, if reward salience and craving become more intense.
8-1	1807-1814	However	_
8-2	1815-1816	,	_
8-3	1817-1821	they	_
8-4	1822-1825	are	_
8-5	1826-1836	compelling	_
8-6	1837-1839	in	_
8-7	1840-1844	that	_
8-8	1845-1849	they	_
8-9	1850-1857	suggest	_
8-10	1858-1862	that	_
8-11	1863-1867	male	_
8-12	1868-1876	military	_
8-13	1877-1885	veterans	_
8-14	1886-1893	cocaine	_
8-15	1894-1899	USERS	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
8-16	1900-1903	are	_
8-17	1904-1916	indefinitely	_
8-18	1917-1919	at	_
8-19	1920-1921	a	_
8-20	1922-1928	higher	_
8-21	1929-1933	risk	_
8-22	1934-1937	for	_
8-23	1938-1944	making	_
8-24	1945-1951	lapses	_
8-25	1952-1954	in	_
8-26	1955-1963	judgment	_
8-27	1964-1967	and	_
8-28	1968-1983	decision-making	_
8-29	1984-1991	leading	_
8-30	1992-1994	to	_
8-31	1995-2003	possible	_
8-32	2004-2011	relapse	_
8-33	2012-2013	,	_
8-34	2014-2016	if	_
8-35	2017-2023	reward	_
8-36	2024-2032	salience	_
8-37	2033-2036	and	_
8-38	2037-2044	craving	_
8-39	2045-2051	become	_
8-40	2052-2056	more	_
8-41	2057-2064	intense	_
8-42	2065-2066	.	_

Text=Understanding the neurobiology of long-term cocaine abstinence in vulnerable populations and beyond could help devising better therapeutic strategies that prevent relapse.
9-1	2067-2080	Understanding	_
9-2	2081-2084	the	_
9-3	2085-2097	neurobiology	_
9-4	2098-2100	of	_
9-5	2101-2110	long-term	_
9-6	2111-2118	cocaine	_
9-7	2119-2129	abstinence	_
9-8	2130-2132	in	_
9-9	2133-2143	vulnerable	_
9-10	2144-2155	populations	_
9-11	2156-2159	and	_
9-12	2160-2166	beyond	_
9-13	2167-2172	could	_
9-14	2173-2177	help	_
9-15	2178-2186	devising	_
9-16	2187-2193	better	_
9-17	2194-2205	therapeutic	_
9-18	2206-2216	strategies	_
9-19	2217-2221	that	_
9-20	2222-2229	prevent	_
9-21	2230-2237	relapse	_
9-22	2238-2239	.	_

Text=Materials and Methods Participants Thirty-nine males (32 cases and 7 controls) from the greater Los Angeles area were recruited to participant in this study.
10-1	2240-2249	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	2250-2253	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	2254-2261	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	2262-2274	Participants	_
10-5	2275-2286	Thirty-nine	_
10-6	2287-2292	males	_
10-7	2293-2294	(	_
10-8	2295-2297	32	_
10-9	2298-2303	cases	http://maven.renci.org/NeuroBridge/neurobridge#CaseControlStudy
10-10	2304-2307	and	_
10-11	2308-2309	7	_
10-12	2310-2318	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-13	2319-2320	)	_
10-14	2321-2325	from	_
10-15	2326-2329	the	_
10-16	2330-2337	greater	_
10-17	2338-2341	Los	_
10-18	2342-2349	Angeles	_
10-19	2350-2354	area	_
10-20	2355-2359	were	_
10-21	2360-2369	recruited	_
10-22	2370-2372	to	_
10-23	2373-2384	participant	_
10-24	2385-2387	in	_
10-25	2388-2392	this	_
10-26	2393-2398	study	_
10-27	2399-2400	.	_

Text=These participants were a subsample of a long-term cohort study investigating the longitudinal patterns and consequences of cocaine use and addiction.
11-1	2401-2406	These	_
11-2	2407-2419	participants	_
11-3	2420-2424	were	_
11-4	2425-2426	a	_
11-5	2427-2436	subsample	_
11-6	2437-2439	of	_
11-7	2440-2441	a	_
11-8	2442-2451	long-term	_
11-9	2452-2458	cohort	_
11-10	2459-2464	study	_
11-11	2465-2478	investigating	_
11-12	2479-2482	the	_
11-13	2483-2495	longitudinal	_
11-14	2496-2504	patterns	_
11-15	2505-2508	and	_
11-16	2509-2521	consequences	_
11-17	2522-2524	of	_
11-18	2525-2532	cocaine	_
11-19	2533-2536	use	_
11-20	2537-2540	and	_
11-21	2541-2550	addiction	_
11-22	2551-2552	.	_

Text=Cocaine-dependent patients were screened and recruited from the original 321 male military veterans who met dependence criteria for cocaine and were admitted to cocaine treatment in 1988–1989.
12-1	2553-2570	Cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
12-2	2571-2579	patients	_
12-3	2580-2584	were	_
12-4	2585-2593	screened	_
12-5	2594-2597	and	_
12-6	2598-2607	recruited	_
12-7	2608-2612	from	_
12-8	2613-2616	the	_
12-9	2617-2625	original	_
12-10	2626-2629	321	_
12-11	2630-2634	male	_
12-12	2635-2643	military	_
12-13	2644-2652	veterans	_
12-14	2653-2656	who	_
12-15	2657-2660	met	_
12-16	2661-2671	dependence	_
12-17	2672-2680	criteria	_
12-18	2681-2684	for	_
12-19	2685-2692	cocaine	_
12-20	2693-2696	and	_
12-21	2697-2701	were	_
12-22	2702-2710	admitted	_
12-23	2711-2713	to	_
12-24	2714-2721	cocaine	_
12-25	2722-2731	treatment	_
12-26	2732-2734	in	_
12-27	2735-2744	1988–1989	_
12-28	2745-2746	.	_

Text=Follow-up interviews were conducted in 1990–1991, 1991–1992, and 2002–2003.
13-1	2747-2756	Follow-up	_
13-2	2757-2767	interviews	_
13-3	2768-2772	were	_
13-4	2773-2782	conducted	_
13-5	2783-2785	in	_
13-6	2786-2795	1990–1991	_
13-7	2796-2797	,	_
13-8	2798-2807	1991–1992	_
13-9	2808-2809	,	_
13-10	2810-2813	and	_
13-11	2814-2823	2002–2003	_
13-12	2824-2825	.	_

Text=The normal control subjects were of similar ages and ethnicity/race; they responded to flyers posted in local Veterans Affairs facilities.
14-1	2826-2829	The	_
14-2	2830-2836	normal	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-3	2837-2844	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-4	2845-2853	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-5	2854-2858	were	_
14-6	2859-2861	of	_
14-7	2862-2869	similar	_
14-8	2870-2874	ages	_
14-9	2875-2878	and	_
14-10	2879-2893	ethnicity/race	_
14-11	2894-2895	;	_
14-12	2896-2900	they	_
14-13	2901-2910	responded	_
14-14	2911-2913	to	_
14-15	2914-2920	flyers	_
14-16	2921-2927	posted	_
14-17	2928-2930	in	_
14-18	2931-2936	local	_
14-19	2937-2945	Veterans	_
14-20	2946-2953	Affairs	_
14-21	2954-2964	facilities	_
14-22	2965-2966	.	_

Text=A screening process was conducted to exclude candidates who: 1) are suffering from Axis 1 psychiatric conditions including PTSD and alcohol dependence; 2) have medical conditions that might interfere with safe study participation; and/or 3) are currently taking medications for psychiatric or medical conditions.
15-1	2967-2968	A	_
15-2	2969-2978	screening	_
15-3	2979-2986	process	_
15-4	2987-2990	was	_
15-5	2991-3000	conducted	_
15-6	3001-3003	to	_
15-7	3004-3011	exclude	_
15-8	3012-3022	candidates	_
15-9	3023-3026	who	_
15-10	3027-3028	:	_
15-11	3029-3030	1	_
15-12	3031-3032	)	_
15-13	3033-3036	are	_
15-14	3037-3046	suffering	_
15-15	3047-3051	from	_
15-16	3052-3056	Axis	_
15-17	3057-3058	1	_
15-18	3059-3070	psychiatric	_
15-19	3071-3081	conditions	_
15-20	3082-3091	including	_
15-21	3092-3096	PTSD	_
15-22	3097-3100	and	_
15-23	3101-3108	alcohol	_
15-24	3109-3119	dependence	_
15-25	3120-3121	;	_
15-26	3122-3123	2	_
15-27	3124-3125	)	_
15-28	3126-3130	have	_
15-29	3131-3138	medical	_
15-30	3139-3149	conditions	_
15-31	3150-3154	that	_
15-32	3155-3160	might	_
15-33	3161-3170	interfere	_
15-34	3171-3175	with	_
15-35	3176-3180	safe	_
15-36	3181-3186	study	_
15-37	3187-3200	participation	_
15-38	3201-3202	;	_
15-39	3203-3209	and/or	_
15-40	3210-3211	3	_
15-41	3212-3213	)	_
15-42	3214-3217	are	_
15-43	3218-3227	currently	_
15-44	3228-3234	taking	_
15-45	3235-3246	medications	_
15-46	3247-3250	for	_
15-47	3251-3262	psychiatric	_
15-48	3263-3265	or	_
15-49	3266-3273	medical	_
15-50	3274-3284	conditions	_
15-51	3285-3286	.	_

Text=A urine testing was also conducted to verify recent self-reported cocaine use or abstinence.
16-1	3287-3288	A	_
16-2	3289-3294	urine	_
16-3	3295-3302	testing	_
16-4	3303-3306	was	_
16-5	3307-3311	also	_
16-6	3312-3321	conducted	_
16-7	3322-3324	to	_
16-8	3325-3331	verify	_
16-9	3332-3338	recent	_
16-10	3339-3352	self-reported	_
16-11	3353-3360	cocaine	_
16-12	3361-3364	use	_
16-13	3365-3367	or	_
16-14	3368-3378	abstinence	_
16-15	3379-3380	.	_

Text=The mean age for these participants was 56.5 ± 5.4 years.
17-1	3381-3384	The	_
17-2	3385-3389	mean	_
17-3	3390-3393	age	_
17-4	3394-3397	for	_
17-5	3398-3403	these	_
17-6	3404-3416	participants	_
17-7	3417-3420	was	_
17-8	3421-3425	56.5	_
17-9	3426-3427	±	_
17-10	3428-3431	5.4	_
17-11	3432-3437	years	_
17-12	3438-3439	.	_

Text=They were in different stages of cocaine abstinence without treatment.
18-1	3440-3444	They	_
18-2	3445-3449	were	_
18-3	3450-3452	in	_
18-4	3453-3462	different	_
18-5	3463-3469	stages	_
18-6	3470-3472	of	_
18-7	3473-3480	cocaine	_
18-8	3481-3491	abstinence	_
18-9	3492-3499	without	_
18-10	3500-3509	treatment	_
18-11	3510-3511	.	_

Text=While twelve were found to use cocaine in the last year (USERS), 20 were at different stages of addiction abstinence (ABSTINENCE) [five with 1-5 years of abstinence (ABS1), five with 6-10 years of abstinence (ABS2), and 10 with over 10 years of abstinence (ABS3)].
19-1	3512-3517	While	_
19-2	3518-3524	twelve	_
19-3	3525-3529	were	_
19-4	3530-3535	found	_
19-5	3536-3538	to	_
19-6	3539-3542	use	_
19-7	3543-3550	cocaine	_
19-8	3551-3553	in	_
19-9	3554-3557	the	_
19-10	3558-3562	last	_
19-11	3563-3567	year	_
19-12	3568-3569	(	_
19-13	3570-3575	USERS	_
19-14	3576-3577	)	_
19-15	3578-3579	,	_
19-16	3580-3582	20	_
19-17	3583-3587	were	_
19-18	3588-3590	at	_
19-19	3591-3600	different	_
19-20	3601-3607	stages	_
19-21	3608-3610	of	_
19-22	3611-3620	addiction	_
19-23	3621-3631	abstinence	_
19-24	3632-3633	(	_
19-25	3634-3644	ABSTINENCE	_
19-26	3645-3646	)	_
19-27	3647-3648	[	_
19-28	3649-3653	five	_
19-29	3654-3658	with	_
19-30	3659-3662	1-5	_
19-31	3663-3668	years	_
19-32	3669-3671	of	_
19-33	3672-3682	abstinence	_
19-34	3683-3684	(	_
19-35	3685-3689	ABS1	_
19-36	3690-3691	)	_
19-37	3692-3693	,	_
19-38	3694-3698	five	_
19-39	3699-3703	with	_
19-40	3704-3708	6-10	_
19-41	3709-3714	years	_
19-42	3715-3717	of	_
19-43	3718-3728	abstinence	_
19-44	3729-3730	(	_
19-45	3731-3735	ABS2	_
19-46	3736-3737	)	_
19-47	3738-3739	,	_
19-48	3740-3743	and	_
19-49	3744-3746	10	_
19-50	3747-3751	with	_
19-51	3752-3756	over	_
19-52	3757-3759	10	_
19-53	3760-3765	years	_
19-54	3766-3768	of	_
19-55	3769-3779	abstinence	_
19-56	3780-3781	(	_
19-57	3782-3786	ABS3	_
19-58	3787-3788	)	_
19-59	3789-3790	]	_
19-60	3791-3792	.	_

Text=The remaining seven subjects were controls (CONTROLS); they had matched age, sex, years of education, and race, to the case subjects.
20-1	3793-3796	The	_
20-2	3797-3806	remaining	_
20-3	3807-3812	seven	_
20-4	3813-3821	subjects	_
20-5	3822-3826	were	_
20-6	3827-3835	controls	_
20-7	3836-3837	(	_
20-8	3838-3846	CONTROLS	_
20-9	3847-3848	)	_
20-10	3849-3850	;	_
20-11	3851-3855	they	_
20-12	3856-3859	had	_
20-13	3860-3867	matched	_
20-14	3868-3871	age	_
20-15	3872-3873	,	_
20-16	3874-3877	sex	_
20-17	3878-3879	,	_
20-18	3880-3885	years	_
20-19	3886-3888	of	_
20-20	3889-3898	education	_
20-21	3899-3900	,	_
20-22	3901-3904	and	_
20-23	3905-3909	race	_
20-24	3910-3911	,	_
20-25	3912-3914	to	_
20-26	3915-3918	the	_
20-27	3919-3923	case	_
20-28	3924-3932	subjects	_
20-29	3933-3934	.	_

Text=The controls never tried cocaine but lived in the same neighborhood.
21-1	3935-3938	The	_
21-2	3939-3947	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-3	3948-3953	never	_
21-4	3954-3959	tried	_
21-5	3960-3967	cocaine	_
21-6	3968-3971	but	_
21-7	3972-3977	lived	_
21-8	3978-3980	in	_
21-9	3981-3984	the	_
21-10	3985-3989	same	_
21-11	3990-4002	neighborhood	_
21-12	4003-4004	.	_

Text=They were carefully screened for any neurological and psychiatric disorders (e.g., current psychoses, anxiety, or bipolar disorders) and use of medications that impact the central nervous system; no exclusions based on these criteria were made.
22-1	4005-4009	They	_
22-2	4010-4014	were	_
22-3	4015-4024	carefully	_
22-4	4025-4033	screened	_
22-5	4034-4037	for	_
22-6	4038-4041	any	_
22-7	4042-4054	neurological	_
22-8	4055-4058	and	_
22-9	4059-4070	psychiatric	_
22-10	4071-4080	disorders	_
22-11	4081-4082	(	_
22-12	4083-4087	e.g.	_
22-13	4088-4089	,	_
22-14	4090-4097	current	_
22-15	4098-4107	psychoses	_
22-16	4108-4109	,	_
22-17	4110-4117	anxiety	_
22-18	4118-4119	,	_
22-19	4120-4122	or	_
22-20	4123-4130	bipolar	_
22-21	4131-4140	disorders	_
22-22	4141-4142	)	_
22-23	4143-4146	and	_
22-24	4147-4150	use	_
22-25	4151-4153	of	_
22-26	4154-4165	medications	_
22-27	4166-4170	that	_
22-28	4171-4177	impact	_
22-29	4178-4181	the	_
22-30	4182-4189	central	_
22-31	4190-4197	nervous	_
22-32	4198-4204	system	_
22-33	4205-4206	;	_
22-34	4207-4209	no	_
22-35	4210-4220	exclusions	_
22-36	4221-4226	based	_
22-37	4227-4229	on	_
22-38	4230-4235	these	_
22-39	4236-4244	criteria	_
22-40	4245-4249	were	_
22-41	4250-4254	made	_
22-42	4255-4256	.	_

Text=All participants had normal or corrected-to-normal vision.
23-1	4257-4260	All	_
23-2	4261-4273	participants	_
23-3	4274-4277	had	_
23-4	4278-4284	normal	_
23-5	4285-4287	or	_
23-6	4288-4307	corrected-to-normal	_
23-7	4308-4314	vision	_
23-8	4315-4316	.	_

Text=All participants gave informed consent to the study procedures, which were approved by Institutional Review Boards of the University of Southern California and the University of California, Los Angeles.
24-1	4317-4320	All	_
24-2	4321-4333	participants	_
24-3	4334-4338	gave	_
24-4	4339-4347	informed	_
24-5	4348-4355	consent	_
24-6	4356-4358	to	_
24-7	4359-4362	the	_
24-8	4363-4368	study	_
24-9	4369-4379	procedures	_
24-10	4380-4381	,	_
24-11	4382-4387	which	_
24-12	4388-4392	were	_
24-13	4393-4401	approved	_
24-14	4402-4404	by	_
24-15	4405-4418	Institutional	_
24-16	4419-4425	Review	_
24-17	4426-4432	Boards	_
24-18	4433-4435	of	_
24-19	4436-4439	the	_
24-20	4440-4450	University	_
24-21	4451-4453	of	_
24-22	4454-4462	Southern	_
24-23	4463-4473	California	_
24-24	4474-4477	and	_
24-25	4478-4481	the	_
24-26	4482-4492	University	_
24-27	4493-4495	of	_
24-28	4496-4506	California	_
24-29	4507-4508	,	_
24-30	4509-4512	Los	_
24-31	4513-4520	Angeles	_
24-32	4521-4522	.	_

Text=Procedures Participants were asked to come to a Cognitive Neuroscience Imaging Center to sign a consent form, complete a behavioral interview and go through an MRI scan.
25-1	4523-4533	Procedures	_
25-2	4534-4546	Participants	_
25-3	4547-4551	were	_
25-4	4552-4557	asked	_
25-5	4558-4560	to	_
25-6	4561-4565	come	_
25-7	4566-4568	to	_
25-8	4569-4570	a	_
25-9	4571-4580	Cognitive	_
25-10	4581-4593	Neuroscience	_
25-11	4594-4601	Imaging	_
25-12	4602-4608	Center	_
25-13	4609-4611	to	_
25-14	4612-4616	sign	_
25-15	4617-4618	a	_
25-16	4619-4626	consent	_
25-17	4627-4631	form	_
25-18	4632-4633	,	_
25-19	4634-4642	complete	_
25-20	4643-4644	a	_
25-21	4645-4655	behavioral	_
25-22	4656-4665	interview	_
25-23	4666-4669	and	_
25-24	4670-4672	go	_
25-25	4673-4680	through	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingDay
25-26	4681-4683	an	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingDay
25-27	4684-4687	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
25-28	4688-4692	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
25-29	4693-4694	.	_

Text=Prior to the MRI scan, they provided a urine sample.
26-1	4695-4700	Prior	_
26-2	4701-4703	to	_
26-3	4704-4707	the	_
26-4	4708-4711	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
26-5	4712-4716	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
26-6	4717-4718	,	_
26-7	4719-4723	they	_
26-8	4724-4732	provided	_
26-9	4733-4734	a	_
26-10	4735-4740	urine	_
26-11	4741-4747	sample	_
26-12	4748-4749	.	_

Text=The MRI scan took about 30 minutes.
27-1	4750-4753	The	_
27-2	4754-4757	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
27-3	4758-4762	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
27-4	4763-4767	took	_
27-5	4768-4773	about	_
27-6	4774-4776	30	_
27-7	4777-4784	minutes	_
27-8	4785-4786	.	_

Text=During the scan, images for one high-resolution structural scan and one session of cue task were acquired, with a short resting period in between.
28-1	4787-4793	During	_
28-2	4794-4797	the	_
28-3	4798-4802	scan	_
28-4	4803-4804	,	_
28-5	4805-4811	images	_
28-6	4812-4815	for	_
28-7	4816-4819	one	_
28-8	4820-4835	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
28-9	4836-4846	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-10	4847-4851	scan	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-11	4852-4855	and	_
28-12	4856-4859	one	_
28-13	4860-4867	session	_
28-14	4868-4870	of	_
28-15	4871-4874	cue	_
28-16	4875-4879	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
28-17	4880-4884	were	_
28-18	4885-4893	acquired	_
28-19	4894-4895	,	_
28-20	4896-4900	with	_
28-21	4901-4902	a	_
28-22	4903-4908	short	_
28-23	4909-4916	resting	_
28-24	4917-4923	period	_
28-25	4924-4926	in	_
28-26	4927-4934	between	_
28-27	4935-4936	.	_

Text=Behavior Interviews Measures included natural history of drug use, alcohol and tobacco use, mental health (e.g., Beck Depression, SCL-58), quality of health (e.g., SF36), sensation-seeking, and self-efficacy.
29-1	4937-4945	Behavior	_
29-2	4946-4956	Interviews	_
29-3	4957-4965	Measures	_
29-4	4966-4974	included	_
29-5	4975-4982	natural	_
29-6	4983-4990	history	_
29-7	4991-4993	of	_
29-8	4994-4998	drug	_
29-9	4999-5002	use	_
29-10	5003-5004	,	_
29-11	5005-5012	alcohol	_
29-12	5013-5016	and	_
29-13	5017-5024	tobacco	_
29-14	5025-5028	use	_
29-15	5029-5030	,	_
29-16	5031-5037	mental	_
29-17	5038-5044	health	_
29-18	5045-5046	(	_
29-19	5047-5051	e.g.	_
29-20	5052-5053	,	_
29-21	5054-5058	Beck	_
29-22	5059-5069	Depression	_
29-23	5070-5071	,	_
29-24	5072-5078	SCL-58	_
29-25	5079-5080	)	_
29-26	5081-5082	,	_
29-27	5083-5090	quality	_
29-28	5091-5093	of	_
29-29	5094-5100	health	_
29-30	5101-5102	(	_
29-31	5103-5107	e.g.	_
29-32	5108-5109	,	_
29-33	5110-5114	SF36	_
29-34	5115-5116	)	_
29-35	5117-5118	,	_
29-36	5119-5136	sensation-seeking	_
29-37	5137-5138	,	_
29-38	5139-5142	and	_
29-39	5143-5156	self-efficacy	_
29-40	5157-5158	.	_

Text=It captured up-to-date drug use and abstinence (e.g., years of cocaine abstinence) and other measures (e.g., current health and mental health).
30-1	5159-5161	It	_
30-2	5162-5170	captured	_
30-3	5171-5181	up-to-date	_
30-4	5182-5186	drug	_
30-5	5187-5190	use	_
30-6	5191-5194	and	_
30-7	5195-5205	abstinence	_
30-8	5206-5207	(	_
30-9	5208-5212	e.g.	_
30-10	5213-5214	,	_
30-11	5215-5220	years	_
30-12	5221-5223	of	_
30-13	5224-5231	cocaine	_
30-14	5232-5242	abstinence	_
30-15	5243-5244	)	_
30-16	5245-5248	and	_
30-17	5249-5254	other	_
30-18	5255-5263	measures	_
30-19	5264-5265	(	_
30-20	5266-5270	e.g.	_
30-21	5271-5272	,	_
30-22	5273-5280	current	_
30-23	5281-5287	health	_
30-24	5288-5291	and	_
30-25	5292-5298	mental	_
30-26	5299-5305	health	_
30-27	5306-5307	)	_
30-28	5308-5309	.	_

Text=Urine samples were used to reasonably confirm participants ’ abstinence.
31-1	5310-5315	Urine	_
31-2	5316-5323	samples	_
31-3	5324-5328	were	_
31-4	5329-5333	used	_
31-5	5334-5336	to	_
31-6	5337-5347	reasonably	_
31-7	5348-5355	confirm	_
31-8	5356-5368	participants	_
31-9	5369-5370	’	_
31-10	5371-5381	abstinence	_
31-11	5382-5383	.	_

Text=fMRI Protocol MRI images were acquired using a 3T Siemens MAGNETOM Tim/Trio scanner at the Dana and David Dornsife Cognitive Neuroscience Imaging Center at the University of Southern California.
32-1	5384-5388	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-2	5389-5397	Protocol	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-3	5398-5401	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-4	5402-5408	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-5	5409-5413	were	_
32-6	5414-5422	acquired	_
32-7	5423-5428	using	_
32-8	5429-5430	a	_
32-9	5431-5433	3T	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
32-10	5434-5441	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
32-11	5442-5450	MAGNETOM	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
32-12	5451-5459	Tim/Trio	_
32-13	5460-5467	scanner	_
32-14	5468-5470	at	_
32-15	5471-5474	the	_
32-16	5475-5479	Dana	_
32-17	5480-5483	and	_
32-18	5484-5489	David	_
32-19	5490-5498	Dornsife	_
32-20	5499-5508	Cognitive	_
32-21	5509-5521	Neuroscience	_
32-22	5522-5529	Imaging	_
32-23	5530-5536	Center	_
32-24	5537-5539	at	_
32-25	5540-5543	the	_
32-26	5544-5554	University	_
32-27	5555-5557	of	_
32-28	5558-5566	Southern	_
32-29	5567-5577	California	_
32-30	5578-5579	.	_

Text=Participants lay in the supine position on the scanner bed.
33-1	5580-5592	Participants	_
33-2	5593-5596	lay	_
33-3	5597-5599	in	_
33-4	5600-5603	the	_
33-5	5604-5610	supine	_
33-6	5611-5619	position	_
33-7	5620-5622	on	_
33-8	5623-5626	the	_
33-9	5627-5634	scanner	_
33-10	5635-5638	bed	_
33-11	5639-5640	.	_

Text=Foam pads were used to minimize head motion.
34-1	5641-5645	Foam	_
34-2	5646-5650	pads	_
34-3	5651-5655	were	_
34-4	5656-5660	used	_
34-5	5661-5663	to	_
34-6	5664-5672	minimize	_
34-7	5673-5677	head	_
34-8	5678-5684	motion	_
34-9	5685-5686	.	_

Text=They were instructed to rest and keep their head very still during the structural scan.
35-1	5687-5691	They	_
35-2	5692-5696	were	_
35-3	5697-5707	instructed	_
35-4	5708-5710	to	_
35-5	5711-5715	rest	_
35-6	5716-5719	and	_
35-7	5720-5724	keep	_
35-8	5725-5730	their	_
35-9	5731-5735	head	_
35-10	5736-5740	very	_
35-11	5741-5746	still	_
35-12	5747-5753	during	_
35-13	5754-5757	the	_
35-14	5758-5768	structural	_
35-15	5769-5773	scan	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
35-16	5774-5775	.	_

Text=During the fMRI scan, the task was back-projected onto a screen through a mirror attached to the head coil.
36-1	5776-5782	During	_
36-2	5783-5786	the	_
36-3	5787-5791	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
36-4	5792-5796	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
36-5	5797-5798	,	_
36-6	5799-5802	the	_
36-7	5803-5807	task	_
36-8	5808-5811	was	_
36-9	5812-5826	back-projected	_
36-10	5827-5831	onto	_
36-11	5832-5833	a	_
36-12	5834-5840	screen	_
36-13	5841-5848	through	_
36-14	5849-5850	a	_
36-15	5851-5857	mirror	_
36-16	5858-5866	attached	_
36-17	5867-5869	to	_
36-18	5870-5873	the	_
36-19	5874-5878	head	_
36-20	5879-5883	coil	_
36-21	5884-5885	.	_

Text=Stimulus presentation and timing of all stimuli and response events were operationalized with Matlab (Mathworks) and Psychtoolbox (www.psychtoolbox.org) on an IBM-compatible PC.
37-1	5886-5894	Stimulus	_
37-2	5895-5907	presentation	_
37-3	5908-5911	and	_
37-4	5912-5918	timing	_
37-5	5919-5921	of	_
37-6	5922-5925	all	_
37-7	5926-5933	stimuli	_
37-8	5934-5937	and	_
37-9	5938-5946	response	_
37-10	5947-5953	events	_
37-11	5954-5958	were	_
37-12	5959-5974	operationalized	_
37-13	5975-5979	with	_
37-14	5980-5986	Matlab	_
37-15	5987-5988	(	_
37-16	5989-5998	Mathworks	_
37-17	5999-6000	)	_
37-18	6001-6004	and	_
37-19	6005-6017	Psychtoolbox	_
37-20	6018-6019	(	_
37-21	6020-6040	www.psychtoolbox.org	_
37-22	6041-6042	)	_
37-23	6043-6045	on	_
37-24	6046-6048	an	_
37-25	6049-6063	IBM-compatible	_
37-26	6064-6066	PC	_
37-27	6067-6068	.	_

Text=Participants ’ responses were collected online using an MRI-compatible button box.
38-1	6069-6081	Participants	_
38-2	6082-6083	’	_
38-3	6084-6093	responses	_
38-4	6094-6098	were	_
38-5	6099-6108	collected	_
38-6	6109-6115	online	_
38-7	6116-6121	using	_
38-8	6122-6124	an	_
38-9	6125-6139	MRI-compatible	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-10	6140-6146	button	_
38-11	6147-6150	box	_
38-12	6151-6152	.	_

Text=The structural image was obtained with T1-weighted 3D-Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence, covering the whole brain with the following scanning parameters: TR/TE = 2530/3.39 ms, flip angel = 7°, matrix = 256 × 256, number of slices = 128, and slice thickness = 1.33 mm.
39-1	6153-6156	The	_
39-2	6157-6167	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
39-3	6168-6173	image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
39-4	6174-6177	was	_
39-5	6178-6186	obtained	_
39-6	6187-6191	with	_
39-7	6192-6203	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-8	6204-6220	3D-Magnetization	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-9	6221-6229	Prepared	_
39-10	6230-6235	Rapid	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
39-11	6236-6244	Gradient	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
39-12	6245-6249	Echo	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
39-13	6250-6251	(	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
39-14	6252-6258	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
39-15	6259-6260	)	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
39-16	6261-6269	sequence	_
39-17	6270-6271	,	_
39-18	6272-6280	covering	_
39-19	6281-6284	the	_
39-20	6285-6290	whole	_
39-21	6291-6296	brain	_
39-22	6297-6301	with	_
39-23	6302-6305	the	_
39-24	6306-6315	following	_
39-25	6316-6324	scanning	_
39-26	6325-6335	parameters	_
39-27	6336-6337	:	_
39-28	6338-6343	TR/TE	_
39-29	6344-6345	=	_
39-30	6346-6355	2530/3.39	_
39-31	6356-6358	ms	_
39-32	6359-6360	,	_
39-33	6361-6365	flip	_
39-34	6366-6371	angel	_
39-35	6372-6373	=	_
39-36	6374-6376	7°	_
39-37	6377-6378	,	_
39-38	6379-6385	matrix	_
39-39	6386-6387	=	_
39-40	6388-6391	256	_
39-41	6392-6393	×	_
39-42	6394-6397	256	_
39-43	6398-6399	,	_
39-44	6400-6406	number	_
39-45	6407-6409	of	_
39-46	6410-6416	slices	_
39-47	6417-6418	=	_
39-48	6419-6422	128	_
39-49	6423-6424	,	_
39-50	6425-6428	and	_
39-51	6429-6434	slice	_
39-52	6435-6444	thickness	_
39-53	6445-6446	=	_
39-54	6447-6451	1.33	_
39-55	6452-6454	mm	_
39-56	6455-6456	.	_

Text=Functional MRI images were acquired with blood oxygen level dependent (BOLD) scan using a z-shim gradient echo EPI (echo planer imaging) sequence with PACE (prospective acquisition correction).
40-1	6457-6467	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-2	6468-6471	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-3	6472-6478	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-4	6479-6483	were	_
40-5	6484-6492	acquired	http://maven.renci.org/NeuroBridge/neurobridge#DiabetesInsipidus
40-6	6493-6497	with	http://maven.renci.org/NeuroBridge/neurobridge#DiabetesInsipidus
40-7	6498-6503	blood	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
40-8	6504-6510	oxygen	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
40-9	6511-6516	level	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
40-10	6517-6526	dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
40-11	6527-6528	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
40-12	6529-6533	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
40-13	6534-6535	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
40-14	6536-6540	scan	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
40-15	6541-6546	using	_
40-16	6547-6548	a	_
40-17	6549-6555	z-shim	_
40-18	6556-6564	gradient	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-19	6565-6569	echo	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-20	6570-6573	EPI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-21	6574-6575	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-22	6576-6580	echo	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-23	6581-6587	planer	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-24	6588-6595	imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-25	6596-6597	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-26	6598-6606	sequence	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-27	6607-6611	with	_
40-28	6612-6616	PACE	_
40-29	6617-6618	(	_
40-30	6619-6630	prospective	_
40-31	6631-6642	acquisition	_
40-32	6643-6653	correction	_
40-33	6654-6655	)	_
40-34	6656-6657	.	_

Text=This specific sequence is designed to reduce signal loss in the prefrontal and orbitofrontal areas.
41-1	6658-6662	This	_
41-2	6663-6671	specific	_
41-3	6672-6680	sequence	_
41-4	6681-6683	is	_
41-5	6684-6692	designed	_
41-6	6693-6695	to	_
41-7	6696-6702	reduce	_
41-8	6703-6709	signal	_
41-9	6710-6714	loss	_
41-10	6715-6717	in	_
41-11	6718-6721	the	_
41-12	6722-6732	prefrontal	_
41-13	6733-6736	and	_
41-14	6737-6750	orbitofrontal	_
41-15	6751-6756	areas	_
41-16	6757-6758	.	_

Text=The PACE option can help reducing the impact of head motion during data acquisition.
42-1	6759-6762	The	_
42-2	6763-6767	PACE	_
42-3	6768-6774	option	_
42-4	6775-6778	can	_
42-5	6779-6783	help	_
42-6	6784-6792	reducing	_
42-7	6793-6796	the	_
42-8	6797-6803	impact	_
42-9	6804-6806	of	_
42-10	6807-6811	head	_
42-11	6812-6818	motion	_
42-12	6819-6825	during	_
42-13	6826-6830	data	_
42-14	6831-6842	acquisition	_
42-15	6843-6844	.	_

Text=The scanning parameters were: TR/TE = 2000/25 ms; flip angle = 90°; 64 × 64 matrix size with resolution 3 × 3 mm2.
43-1	6845-6848	The	_
43-2	6849-6857	scanning	_
43-3	6858-6868	parameters	_
43-4	6869-6873	were	_
43-5	6874-6875	:	_
43-6	6876-6881	TR/TE	_
43-7	6882-6883	=	_
43-8	6884-6891	2000/25	_
43-9	6892-6894	ms	_
43-10	6895-6896	;	_
43-11	6897-6901	flip	_
43-12	6902-6907	angle	_
43-13	6908-6909	=	_
43-14	6910-6913	90°	_
43-15	6914-6915	;	_
43-16	6916-6918	64	_
43-17	6919-6920	×	_
43-18	6921-6923	64	_
43-19	6924-6930	matrix	_
43-20	6931-6935	size	_
43-21	6936-6940	with	_
43-22	6941-6951	resolution	_
43-23	6952-6953	3	_
43-24	6954-6955	×	_
43-25	6956-6957	3	_
43-26	6958-6961	mm2	_
43-27	6962-6963	.	_

Text=Thirty-one 3.5-mm axial slices were used to cover the whole cerebral cortex and most of the cerebellum with no gaps.
44-1	6964-6974	Thirty-one	_
44-2	6975-6981	3.5-mm	_
44-3	6982-6987	axial	_
44-4	6988-6994	slices	_
44-5	6995-6999	were	_
44-6	7000-7004	used	_
44-7	7005-7007	to	_
44-8	7008-7013	cover	_
44-9	7014-7017	the	_
44-10	7018-7023	whole	_
44-11	7024-7032	cerebral	_
44-12	7033-7039	cortex	_
44-13	7040-7043	and	_
44-14	7044-7048	most	_
44-15	7049-7051	of	_
44-16	7052-7055	the	_
44-17	7056-7066	cerebellum	_
44-18	7067-7071	with	_
44-19	7072-7074	no	_
44-20	7075-7079	gaps	_
44-21	7080-7081	.	_

Text=The slices were tilted about 30° clockwise along the AC-PC plane to obtain better signals in the orbitofrontal cortex.
45-1	7082-7085	The	_
45-2	7086-7092	slices	_
45-3	7093-7097	were	_
45-4	7098-7104	tilted	_
45-5	7105-7110	about	_
45-6	7111-7114	30°	_
45-7	7115-7124	clockwise	_
45-8	7125-7130	along	_
45-9	7131-7134	the	_
45-10	7135-7140	AC-PC	_
45-11	7141-7146	plane	_
45-12	7147-7149	to	_
45-13	7150-7156	obtain	_
45-14	7157-7163	better	_
45-15	7164-7171	signals	_
45-16	7172-7174	in	_
45-17	7175-7178	the	_
45-18	7179-7192	orbitofrontal	_
45-19	7193-7199	cortex	_
45-20	7200-7201	.	_

Text=fMRI Cue Task Participants performed a cue task in the scanner to measure their brain activity when watching two categories of stimuli: cocaine-related pictures and natural scene pictures (see example stimuli in Figure 1).
46-1	7202-7206	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-2	7207-7210	Cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-3	7211-7215	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-4	7216-7228	Participants	_
46-5	7229-7238	performed	_
46-6	7239-7240	a	_
46-7	7241-7244	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-8	7245-7249	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-9	7250-7252	in	_
46-10	7253-7256	the	_
46-11	7257-7264	scanner	_
46-12	7265-7267	to	_
46-13	7268-7275	measure	_
46-14	7276-7281	their	_
46-15	7282-7287	brain	_
46-16	7288-7296	activity	_
46-17	7297-7301	when	_
46-18	7302-7310	watching	_
46-19	7311-7314	two	_
46-20	7315-7325	categories	_
46-21	7326-7328	of	_
46-22	7329-7336	stimuli	_
46-23	7337-7338	:	_
46-24	7339-7354	cocaine-related	_
46-25	7355-7363	pictures	_
46-26	7364-7367	and	_
46-27	7368-7375	natural	_
46-28	7376-7381	scene	_
46-29	7382-7390	pictures	_
46-30	7391-7392	(	_
46-31	7393-7396	see	_
46-32	7397-7404	example	_
46-33	7405-7412	stimuli	_
46-34	7413-7415	in	_
46-35	7416-7422	Figure	_
46-36	7423-7424	1	_
46-37	7425-7426	)	_
46-38	7427-7428	.	_

Text=The fMRI task used a block design and participants were asked to passively view the images.
47-1	7429-7432	The	_
47-2	7433-7437	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
47-3	7438-7442	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
47-4	7443-7447	used	_
47-5	7448-7449	a	_
47-6	7450-7455	block	_
47-7	7456-7462	design	_
47-8	7463-7466	and	_
47-9	7467-7479	participants	_
47-10	7480-7484	were	_
47-11	7485-7490	asked	_
47-12	7491-7493	to	_
47-13	7494-7503	passively	_
47-14	7504-7508	view	_
47-15	7509-7512	the	_
47-16	7513-7519	images	_
47-17	7520-7521	.	_

Text=MRI-compatible eye-tracking system was used to monitor participants ’ pupils to ensure they are awake during the fMRI task.
48-1	7522-7536	MRI-compatible	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
48-2	7537-7549	eye-tracking	_
48-3	7550-7556	system	_
48-4	7557-7560	was	_
48-5	7561-7565	used	_
48-6	7566-7568	to	_
48-7	7569-7576	monitor	_
48-8	7577-7589	participants	_
48-9	7590-7591	’	_
48-10	7592-7598	pupils	_
48-11	7599-7601	to	_
48-12	7602-7608	ensure	_
48-13	7609-7613	they	_
48-14	7614-7617	are	_
48-15	7618-7623	awake	_
48-16	7624-7630	during	_
48-17	7631-7634	the	_
48-18	7635-7639	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
48-19	7640-7644	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
48-20	7645-7646	.	_

Text=No exclusions based on this were made.
49-1	7647-7649	No	_
49-2	7650-7660	exclusions	_
49-3	7661-7666	based	_
49-4	7667-7669	on	_
49-5	7670-7674	this	_
49-6	7675-7679	were	_
49-7	7680-7684	made	_
49-8	7685-7686	.	_

Text=Within each 24 second block, 8 pictures were presented for 2.5 second each with an inter-trial interval of 0.5 seconds.
50-1	7687-7693	Within	_
50-2	7694-7698	each	_
50-3	7699-7701	24	_
50-4	7702-7708	second	_
50-5	7709-7714	block	_
50-6	7715-7716	,	_
50-7	7717-7718	8	_
50-8	7719-7727	pictures	_
50-9	7728-7732	were	_
50-10	7733-7742	presented	_
50-11	7743-7746	for	_
50-12	7747-7750	2.5	_
50-13	7751-7757	second	_
50-14	7758-7762	each	_
50-15	7763-7767	with	_
50-16	7768-7770	an	_
50-17	7771-7782	inter-trial	_
50-18	7783-7791	interval	_
50-19	7792-7794	of	_
50-20	7795-7798	0.5	_
50-21	7799-7806	seconds	_
50-22	7807-7808	.	_

Text=There was a 12 second resting period between blocks of stimuli.
51-1	7809-7814	There	_
51-2	7815-7818	was	_
51-3	7819-7820	a	_
51-4	7821-7823	12	_
51-5	7824-7830	second	_
51-6	7831-7838	resting	_
51-7	7839-7845	period	_
51-8	7846-7853	between	_
51-9	7854-7860	blocks	_
51-10	7861-7863	of	_
51-11	7864-7871	stimuli	_
51-12	7872-7873	.	_

Text=There were 16 cocaine-related pictures and 16 natural scene pictures.
52-1	7874-7879	There	_
52-2	7880-7884	were	_
52-3	7885-7887	16	_
52-4	7888-7903	cocaine-related	_
52-5	7904-7912	pictures	_
52-6	7913-7916	and	_
52-7	7917-7919	16	_
52-8	7920-7927	natural	_
52-9	7928-7933	scene	_
52-10	7934-7942	pictures	_
52-11	7943-7944	.	_

Text=These pictures were selected based on a pilot study.
53-1	7945-7950	These	_
53-2	7951-7959	pictures	_
53-3	7960-7964	were	_
53-4	7965-7973	selected	_
53-5	7974-7979	based	_
53-6	7980-7982	on	_
53-7	7983-7984	a	_
53-8	7985-7990	pilot	_
53-9	7991-7996	study	_
53-10	7997-7998	.	_

Text=Each participant viewed 8 blocks of each stimuli type and the order of different stimuli presentation was counterbalanced across participants using either ABBABAAB or BAABABBA sequence.
54-1	7999-8003	Each	_
54-2	8004-8015	participant	_
54-3	8016-8022	viewed	_
54-4	8023-8024	8	_
54-5	8025-8031	blocks	_
54-6	8032-8034	of	_
54-7	8035-8039	each	_
54-8	8040-8047	stimuli	_
54-9	8048-8052	type	_
54-10	8053-8056	and	_
54-11	8057-8060	the	_
54-12	8061-8066	order	_
54-13	8067-8069	of	_
54-14	8070-8079	different	_
54-15	8080-8087	stimuli	_
54-16	8088-8100	presentation	_
54-17	8101-8104	was	_
54-18	8105-8120	counterbalanced	_
54-19	8121-8127	across	_
54-20	8128-8140	participants	_
54-21	8141-8146	using	_
54-22	8147-8153	either	_
54-23	8154-8162	ABBABAAB	_
54-24	8163-8165	or	_
54-25	8166-8174	BAABABBA	_
54-26	8175-8183	sequence	_
54-27	8184-8185	.	_

Text=There was a 12 second resting period both at the beginning and the end of the task.
55-1	8186-8191	There	_
55-2	8192-8195	was	_
55-3	8196-8197	a	_
55-4	8198-8200	12	_
55-5	8201-8207	second	_
55-6	8208-8215	resting	_
55-7	8216-8222	period	_
55-8	8223-8227	both	_
55-9	8228-8230	at	_
55-10	8231-8234	the	_
55-11	8235-8244	beginning	_
55-12	8245-8248	and	_
55-13	8249-8252	the	_
55-14	8253-8256	end	_
55-15	8257-8259	of	_
55-16	8260-8263	the	_
55-17	8264-8268	task	_
55-18	8269-8270	.	_

Text=The total scanning time for the cue task was about 10 minutes.
56-1	8271-8274	The	_
56-2	8275-8280	total	_
56-3	8281-8289	scanning	_
56-4	8290-8294	time	_
56-5	8295-8298	for	_
56-6	8299-8302	the	_
56-7	8303-8306	cue	_
56-8	8307-8311	task	_
56-9	8312-8315	was	_
56-10	8316-8321	about	_
56-11	8322-8324	10	_
56-12	8325-8332	minutes	_
56-13	8333-8334	.	_

Text=Statistical Analysis Similar analysis procedures were applied to the structural and functional scans.
57-1	8335-8346	Statistical	_
57-2	8347-8355	Analysis	_
57-3	8356-8363	Similar	_
57-4	8364-8372	analysis	_
57-5	8373-8383	procedures	_
57-6	8384-8388	were	_
57-7	8389-8396	applied	_
57-8	8397-8399	to	_
57-9	8400-8403	the	_
57-10	8404-8414	structural	_
57-11	8415-8418	and	_
57-12	8419-8429	functional	_
57-13	8430-8435	scans	_
57-14	8436-8437	.	_

Text=First, participants were divided into three major groups: USERS (those who have used cocaine within the last year, n = 12), ABSTINENCE (those who were at different stages of cocaine abstinence, n = 20) and CONTROLS (matched controls that have never used cocaine, n = 7).
58-1	8438-8443	First	_
58-2	8444-8445	,	_
58-3	8446-8458	participants	_
58-4	8459-8463	were	_
58-5	8464-8471	divided	_
58-6	8472-8476	into	_
58-7	8477-8482	three	_
58-8	8483-8488	major	_
58-9	8489-8495	groups	_
58-10	8496-8497	:	_
58-11	8498-8503	USERS	_
58-12	8504-8505	(	_
58-13	8506-8511	those	_
58-14	8512-8515	who	_
58-15	8516-8520	have	_
58-16	8521-8525	used	_
58-17	8526-8533	cocaine	_
58-18	8534-8540	within	_
58-19	8541-8544	the	_
58-20	8545-8549	last	_
58-21	8550-8554	year	_
58-22	8555-8556	,	_
58-23	8557-8558	n	_
58-24	8559-8560	=	_
58-25	8561-8563	12	_
58-26	8564-8565	)	_
58-27	8566-8567	,	_
58-28	8568-8578	ABSTINENCE	_
58-29	8579-8580	(	_
58-30	8581-8586	those	_
58-31	8587-8590	who	_
58-32	8591-8595	were	_
58-33	8596-8598	at	_
58-34	8599-8608	different	_
58-35	8609-8615	stages	_
58-36	8616-8618	of	_
58-37	8619-8626	cocaine	_
58-38	8627-8637	abstinence	_
58-39	8638-8639	,	_
58-40	8640-8641	n	_
58-41	8642-8643	=	_
58-42	8644-8646	20	_
58-43	8647-8648	)	_
58-44	8649-8652	and	_
58-45	8653-8661	CONTROLS	_
58-46	8662-8663	(	_
58-47	8664-8671	matched	_
58-48	8672-8680	controls	_
58-49	8681-8685	that	_
58-50	8686-8690	have	_
58-51	8691-8696	never	_
58-52	8697-8701	used	_
58-53	8702-8709	cocaine	_
58-54	8710-8711	,	_
58-55	8712-8713	n	_
58-56	8714-8715	=	_
58-57	8716-8717	7	_
58-58	8718-8719	)	_
58-59	8720-8721	.	_

Text=The first analysis focused on group differences between 1) USERS and CONTROLS, 2) USERS and ABSTINENCE, 3) ABSTINENCE and CONTROLS.
59-1	8722-8725	The	_
59-2	8726-8731	first	_
59-3	8732-8740	analysis	_
59-4	8741-8748	focused	_
59-5	8749-8751	on	_
59-6	8752-8757	group	_
59-7	8758-8769	differences	_
59-8	8770-8777	between	_
59-9	8778-8779	1	_
59-10	8780-8781	)	_
59-11	8782-8787	USERS	_
59-12	8788-8791	and	_
59-13	8792-8800	CONTROLS	_
59-14	8801-8802	,	_
59-15	8803-8804	2	_
59-16	8805-8806	)	_
59-17	8807-8812	USERS	_
59-18	8813-8816	and	_
59-19	8817-8827	ABSTINENCE	_
59-20	8828-8829	,	_
59-21	8830-8831	3	_
59-22	8832-8833	)	_
59-23	8834-8844	ABSTINENCE	_
59-24	8845-8848	and	_
59-25	8849-8857	CONTROLS	_
59-26	8858-8859	.	_

Text=Since the number of participants in the CONTROL group was relatively small, we first examined group difference between three groups as a means to preliminarily search for brain regions that may present differences.
60-1	8860-8865	Since	_
60-2	8866-8869	the	_
60-3	8870-8876	number	_
60-4	8877-8879	of	_
60-5	8880-8892	participants	_
60-6	8893-8895	in	_
60-7	8896-8899	the	_
60-8	8900-8907	CONTROL	_
60-9	8908-8913	group	_
60-10	8914-8917	was	_
60-11	8918-8928	relatively	_
60-12	8929-8934	small	_
60-13	8935-8936	,	_
60-14	8937-8939	we	_
60-15	8940-8945	first	_
60-16	8946-8954	examined	_
60-17	8955-8960	group	_
60-18	8961-8971	difference	_
60-19	8972-8979	between	_
60-20	8980-8985	three	_
60-21	8986-8992	groups	_
60-22	8993-8995	as	_
60-23	8996-8997	a	_
60-24	8998-9003	means	_
60-25	9004-9006	to	_
60-26	9007-9020	preliminarily	_
60-27	9021-9027	search	_
60-28	9028-9031	for	_
60-29	9032-9037	brain	_
60-30	9038-9045	regions	_
60-31	9046-9050	that	_
60-32	9051-9054	may	_
60-33	9055-9062	present	_
60-34	9063-9074	differences	_
60-35	9075-9076	.	_

Text=These differences were further refined by dividing the ABSTINENCE group into three subgroups: ABS1 (1–5 years of abstinence, n = 5), ABS2 (6–10 years of abstinence, n = 5), and ABS3 (abstinent for over 10 years, n = 10).
61-1	9077-9082	These	_
61-2	9083-9094	differences	_
61-3	9095-9099	were	_
61-4	9100-9107	further	_
61-5	9108-9115	refined	_
61-6	9116-9118	by	_
61-7	9119-9127	dividing	_
61-8	9128-9131	the	_
61-9	9132-9142	ABSTINENCE	_
61-10	9143-9148	group	_
61-11	9149-9153	into	_
61-12	9154-9159	three	_
61-13	9160-9169	subgroups	_
61-14	9170-9171	:	_
61-15	9172-9176	ABS1	_
61-16	9177-9178	(	_
61-17	9179-9182	1–5	_
61-18	9183-9188	years	_
61-19	9189-9191	of	_
61-20	9192-9202	abstinence	_
61-21	9203-9204	,	_
61-22	9205-9206	n	_
61-23	9207-9208	=	_
61-24	9209-9210	5	_
61-25	9211-9212	)	_
61-26	9213-9214	,	_
61-27	9215-9219	ABS2	_
61-28	9220-9221	(	_
61-29	9222-9226	6–10	_
61-30	9227-9232	years	_
61-31	9233-9235	of	_
61-32	9236-9246	abstinence	_
61-33	9247-9248	,	_
61-34	9249-9250	n	_
61-35	9251-9252	=	_
61-36	9253-9254	5	_
61-37	9255-9256	)	_
61-38	9257-9258	,	_
61-39	9259-9262	and	_
61-40	9263-9267	ABS3	_
61-41	9268-9269	(	_
61-42	9270-9279	abstinent	_
61-43	9280-9283	for	_
61-44	9284-9288	over	_
61-45	9289-9291	10	_
61-46	9292-9297	years	_
61-47	9298-9299	,	_
61-48	9300-9301	n	_
61-49	9302-9303	=	_
61-50	9304-9306	10	_
61-51	9307-9308	)	_
61-52	9309-9310	.	_

Text=This division was chosen based on how prior research has treated short meaningful abstinence, medium duration abstinence, and long-term abstinence.
62-1	9311-9315	This	_
62-2	9316-9324	division	_
62-3	9325-9328	was	_
62-4	9329-9335	chosen	_
62-5	9336-9341	based	_
62-6	9342-9344	on	_
62-7	9345-9348	how	_
62-8	9349-9354	prior	_
62-9	9355-9363	research	_
62-10	9364-9367	has	_
62-11	9368-9375	treated	_
62-12	9376-9381	short	_
62-13	9382-9392	meaningful	_
62-14	9393-9403	abstinence	_
62-15	9404-9405	,	_
62-16	9406-9412	medium	_
62-17	9413-9421	duration	_
62-18	9422-9432	abstinence	_
62-19	9433-9434	,	_
62-20	9435-9438	and	_
62-21	9439-9448	long-term	_
62-22	9449-9459	abstinence	_
62-23	9460-9461	.	_

Text=A second analysis was performed to shed more light on possible differences associated with abstinence.
63-1	9462-9463	A	_
63-2	9464-9470	second	_
63-3	9471-9479	analysis	_
63-4	9480-9483	was	_
63-5	9484-9493	performed	_
63-6	9494-9496	to	_
63-7	9497-9501	shed	_
63-8	9502-9506	more	_
63-9	9507-9512	light	_
63-10	9513-9515	on	_
63-11	9516-9524	possible	_
63-12	9525-9536	differences	_
63-13	9537-9547	associated	_
63-14	9548-9552	with	_
63-15	9553-9563	abstinence	_
63-16	9564-9565	.	_

Text=It included two inter-group comparisons between: 1) USERS and ABS1 (examining the differences between current users and recently abstinent); and 2) CONTROL and ABS3 (examining the differences between controls and long term abstinent).
64-1	9566-9568	It	_
64-2	9569-9577	included	_
64-3	9578-9581	two	_
64-4	9582-9593	inter-group	_
64-5	9594-9605	comparisons	_
64-6	9606-9613	between	_
64-7	9614-9615	:	_
64-8	9616-9617	1	_
64-9	9618-9619	)	_
64-10	9620-9625	USERS	_
64-11	9626-9629	and	_
64-12	9630-9634	ABS1	_
64-13	9635-9636	(	_
64-14	9637-9646	examining	_
64-15	9647-9650	the	_
64-16	9651-9662	differences	_
64-17	9663-9670	between	_
64-18	9671-9678	current	_
64-19	9679-9684	users	_
64-20	9685-9688	and	_
64-21	9689-9697	recently	_
64-22	9698-9707	abstinent	_
64-23	9708-9709	)	_
64-24	9710-9711	;	_
64-25	9712-9715	and	_
64-26	9716-9717	2	_
64-27	9718-9719	)	_
64-28	9720-9727	CONTROL	_
64-29	9728-9731	and	_
64-30	9732-9736	ABS3	_
64-31	9737-9738	(	_
64-32	9739-9748	examining	_
64-33	9749-9752	the	_
64-34	9753-9764	differences	_
64-35	9765-9772	between	_
64-36	9773-9781	controls	_
64-37	9782-9785	and	_
64-38	9786-9790	long	_
64-39	9791-9795	term	_
64-40	9796-9805	abstinent	_
64-41	9806-9807	)	_
64-42	9808-9809	.	_

Text=A third analysis included the calculation of years of abstinence for the ABSTINENCE group (N = 20).
65-1	9810-9811	A	_
65-2	9812-9817	third	_
65-3	9818-9826	analysis	_
65-4	9827-9835	included	_
65-5	9836-9839	the	_
65-6	9840-9851	calculation	_
65-7	9852-9854	of	_
65-8	9855-9860	years	_
65-9	9861-9863	of	_
65-10	9864-9874	abstinence	_
65-11	9875-9878	for	_
65-12	9879-9882	the	_
65-13	9883-9893	ABSTINENCE	_
65-14	9894-9899	group	_
65-15	9900-9901	(	_
65-16	9902-9903	N	_
65-17	9904-9905	=	_
65-18	9906-9908	20	_
65-19	9909-9910	)	_
65-20	9911-9912	.	_

Text=These data and their log10 transformation were then correlated with whole-brain imaging data.
66-1	9913-9918	These	_
66-2	9919-9923	data	_
66-3	9924-9927	and	_
66-4	9928-9933	their	_
66-5	9934-9939	log10	_
66-6	9940-9954	transformation	_
66-7	9955-9959	were	_
66-8	9960-9964	then	_
66-9	9965-9975	correlated	_
66-10	9976-9980	with	_
66-11	9981-9992	whole-brain	_
66-12	9993-10000	imaging	_
66-13	10001-10005	data	_
66-14	10006-10007	.	_

Text=This was done to reveal association between abstinence duration and brain function and structure.
67-1	10008-10012	This	_
67-2	10013-10016	was	_
67-3	10017-10021	done	_
67-4	10022-10024	to	_
67-5	10025-10031	reveal	_
67-6	10032-10043	association	_
67-7	10044-10051	between	_
67-8	10052-10062	abstinence	_
67-9	10063-10071	duration	_
67-10	10072-10075	and	_
67-11	10076-10081	brain	_
67-12	10082-10090	function	_
67-13	10091-10094	and	_
67-14	10095-10104	structure	_
67-15	10105-10106	.	_

Text=The last (fourth) analysis supplemented the previous one by extracting region of interest (ROI) volumes and activations.
68-1	10107-10110	The	_
68-2	10111-10115	last	_
68-3	10116-10117	(	_
68-4	10118-10124	fourth	_
68-5	10125-10126	)	_
68-6	10127-10135	analysis	_
68-7	10136-10148	supplemented	_
68-8	10149-10152	the	_
68-9	10153-10161	previous	_
68-10	10162-10165	one	_
68-11	10166-10168	by	_
68-12	10169-10179	extracting	_
68-13	10180-10186	region	_
68-14	10187-10189	of	_
68-15	10190-10198	interest	_
68-16	10199-10200	(	_
68-17	10201-10204	ROI	_
68-18	10205-10206	)	_
68-19	10207-10214	volumes	_
68-20	10215-10218	and	_
68-21	10219-10230	activations	_
68-22	10231-10232	.	_

Text=These data were used for subgroup comparisons.
69-1	10233-10238	These	_
69-2	10239-10243	data	_
69-3	10244-10248	were	_
69-4	10249-10253	used	_
69-5	10254-10257	for	_
69-6	10258-10266	subgroup	_
69-7	10267-10278	comparisons	_
69-8	10279-10280	.	_

Text=For all correlational analysis, robust regression was used to minimize the impact of outliers in the behavioral data, using iteratively reweighted least squares implemented in the robustfit command in the MATLAB Statistics Toolbox.
70-1	10281-10284	For	_
70-2	10285-10288	all	_
70-3	10289-10302	correlational	_
70-4	10303-10311	analysis	_
70-5	10312-10313	,	_
70-6	10314-10320	robust	_
70-7	10321-10331	regression	_
70-8	10332-10335	was	_
70-9	10336-10340	used	_
70-10	10341-10343	to	_
70-11	10344-10352	minimize	_
70-12	10353-10356	the	_
70-13	10357-10363	impact	_
70-14	10364-10366	of	_
70-15	10367-10375	outliers	_
70-16	10376-10378	in	_
70-17	10379-10382	the	_
70-18	10383-10393	behavioral	_
70-19	10394-10398	data	_
70-20	10399-10400	,	_
70-21	10401-10406	using	_
70-22	10407-10418	iteratively	_
70-23	10419-10429	reweighted	_
70-24	10430-10435	least	_
70-25	10436-10443	squares	_
70-26	10444-10455	implemented	_
70-27	10456-10458	in	_
70-28	10459-10462	the	_
70-29	10463-10472	robustfit	_
70-30	10473-10480	command	_
70-31	10481-10483	in	_
70-32	10484-10487	the	_
70-33	10488-10494	MATLAB	_
70-34	10495-10505	Statistics	_
70-35	10506-10513	Toolbox	_
70-36	10514-10515	.	_

Text=Reported r-values reflect (non-robust) Pearson product-moment correlation values, whereas the reported p-values and regression lines are based on the robust regression results.
71-1	10516-10524	Reported	_
71-2	10525-10533	r-values	_
71-3	10534-10541	reflect	_
71-4	10542-10543	(	_
71-5	10544-10554	non-robust	_
71-6	10555-10556	)	_
71-7	10557-10564	Pearson	_
71-8	10565-10579	product-moment	_
71-9	10580-10591	correlation	_
71-10	10592-10598	values	_
71-11	10599-10600	,	_
71-12	10601-10608	whereas	_
71-13	10609-10612	the	_
71-14	10613-10621	reported	_
71-15	10622-10630	p-values	_
71-16	10631-10634	and	_
71-17	10635-10645	regression	_
71-18	10646-10651	lines	_
71-19	10652-10655	are	_
71-20	10656-10661	based	_
71-21	10662-10664	on	_
71-22	10665-10668	the	_
71-23	10669-10675	robust	_
71-24	10676-10686	regression	_
71-25	10687-10694	results	_
71-26	10695-10696	.	_

Text=Because the sample size was relatively small, the effect sizes as well as their 95% confidence intervals were reported where available, following methods by.
72-1	10697-10704	Because	_
72-2	10705-10708	the	_
72-3	10709-10715	sample	_
72-4	10716-10720	size	_
72-5	10721-10724	was	_
72-6	10725-10735	relatively	_
72-7	10736-10741	small	_
72-8	10742-10743	,	_
72-9	10744-10747	the	_
72-10	10748-10754	effect	_
72-11	10755-10760	sizes	_
72-12	10761-10763	as	_
72-13	10764-10768	well	_
72-14	10769-10771	as	_
72-15	10772-10777	their	_
72-16	10778-10780	95	_
72-17	10781-10782	%	_
72-18	10783-10793	confidence	_
72-19	10794-10803	intervals	_
72-20	10804-10808	were	_
72-21	10809-10817	reported	_
72-22	10818-10823	where	_
72-23	10824-10833	available	_
72-24	10834-10835	,	_
72-25	10836-10845	following	_
72-26	10846-10853	methods	_
72-27	10854-10856	by	_
72-28	10857-10858	.	_

Text=Voxel-Based Morphometry (VBM) Analysis Structural MRI data were analyzed with FSL-VBM, an optimized voxel-based morphometry analysis toolbox implemented in FSL.
73-1	10859-10870	Voxel-Based	_
73-2	10871-10882	Morphometry	_
73-3	10883-10884	(	_
73-4	10885-10888	VBM	_
73-5	10889-10890	)	_
73-6	10891-10899	Analysis	_
73-7	10900-10910	Structural	_
73-8	10911-10914	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
73-9	10915-10919	data	_
73-10	10920-10924	were	_
73-11	10925-10933	analyzed	_
73-12	10934-10938	with	_
73-13	10939-10946	FSL-VBM	_
73-14	10947-10948	,	_
73-15	10949-10951	an	_
73-16	10952-10961	optimized	_
73-17	10962-10973	voxel-based	_
73-18	10974-10985	morphometry	_
73-19	10986-10994	analysis	_
73-20	10995-11002	toolbox	_
73-21	11003-11014	implemented	_
73-22	11015-11017	in	_
73-23	11018-11021	FSL	_
73-24	11022-11023	.	_

Text=This approach requires no prior information about the location of possible differences in gray matter, and has been proven to be operator-independent.
74-1	11024-11028	This	_
74-2	11029-11037	approach	_
74-3	11038-11046	requires	_
74-4	11047-11049	no	_
74-5	11050-11055	prior	_
74-6	11056-11067	information	_
74-7	11068-11073	about	_
74-8	11074-11077	the	_
74-9	11078-11086	location	_
74-10	11087-11089	of	_
74-11	11090-11098	possible	_
74-12	11099-11110	differences	_
74-13	11111-11113	in	_
74-14	11114-11118	gray	_
74-15	11119-11125	matter	_
74-16	11126-11127	,	_
74-17	11128-11131	and	_
74-18	11132-11135	has	_
74-19	11136-11140	been	_
74-20	11141-11147	proven	_
74-21	11148-11150	to	_
74-22	11151-11153	be	_
74-23	11154-11174	operator-independent	_
74-24	11175-11176	.	_

Text=First, structural images were extracted using BET.
75-1	11177-11182	First	_
75-2	11183-11184	,	_
75-3	11185-11195	structural	_
75-4	11196-11202	images	_
75-5	11203-11207	were	_
75-6	11208-11217	extracted	_
75-7	11218-11223	using	_
75-8	11224-11227	BET	_
75-9	11228-11229	.	_

Text=Next, tissue-type segmentation was performed using FAST4.
76-1	11230-11234	Next	_
76-2	11235-11236	,	_
76-3	11237-11248	tissue-type	_
76-4	11249-11261	segmentation	_
76-5	11262-11265	was	_
76-6	11266-11275	performed	_
76-7	11276-11281	using	_
76-8	11282-11287	FAST4	_
76-9	11288-11289	.	_

Text=The resulting gray-matter partial volume images were then aligned to the gray-matter template in the MNI152 standard space using the affine registration tool FLIRT, followed by nonlinear registration using FNIRT, which used a b-spline representation of the registration warp field.
77-1	11290-11293	The	_
77-2	11294-11303	resulting	_
77-3	11304-11315	gray-matter	_
77-4	11316-11323	partial	_
77-5	11324-11330	volume	_
77-6	11331-11337	images	_
77-7	11338-11342	were	_
77-8	11343-11347	then	_
77-9	11348-11355	aligned	_
77-10	11356-11358	to	_
77-11	11359-11362	the	_
77-12	11363-11374	gray-matter	_
77-13	11375-11383	template	_
77-14	11384-11386	in	_
77-15	11387-11390	the	_
77-16	11391-11397	MNI152	_
77-17	11398-11406	standard	_
77-18	11407-11412	space	_
77-19	11413-11418	using	_
77-20	11419-11422	the	_
77-21	11423-11429	affine	_
77-22	11430-11442	registration	_
77-23	11443-11447	tool	_
77-24	11448-11453	FLIRT	_
77-25	11454-11455	,	_
77-26	11456-11464	followed	_
77-27	11465-11467	by	_
77-28	11468-11477	nonlinear	_
77-29	11478-11490	registration	_
77-30	11491-11496	using	_
77-31	11497-11502	FNIRT	_
77-32	11503-11504	,	_
77-33	11505-11510	which	_
77-34	11511-11515	used	_
77-35	11516-11517	a	_
77-36	11518-11526	b-spline	_
77-37	11527-11541	representation	_
77-38	11542-11544	of	_
77-39	11545-11548	the	_
77-40	11549-11561	registration	_
77-41	11562-11566	warp	_
77-42	11567-11572	field	_
77-43	11573-11574	.	_

Text=The spatially normalized images were then averaged to create a study-specific template, to which the native gray matter images were registered again using both linear and nonlinear algorithms as described above.
78-1	11575-11578	The	_
78-2	11579-11588	spatially	_
78-3	11589-11599	normalized	_
78-4	11600-11606	images	_
78-5	11607-11611	were	_
78-6	11612-11616	then	_
78-7	11617-11625	averaged	_
78-8	11626-11628	to	_
78-9	11629-11635	create	_
78-10	11636-11637	a	_
78-11	11638-11652	study-specific	_
78-12	11653-11661	template	_
78-13	11662-11663	,	_
78-14	11664-11666	to	_
78-15	11667-11672	which	_
78-16	11673-11676	the	_
78-17	11677-11683	native	_
78-18	11684-11688	gray	_
78-19	11689-11695	matter	_
78-20	11696-11702	images	_
78-21	11703-11707	were	_
78-22	11708-11718	registered	_
78-23	11719-11724	again	_
78-24	11725-11730	using	_
78-25	11731-11735	both	_
78-26	11736-11742	linear	_
78-27	11743-11746	and	_
78-28	11747-11756	nonlinear	_
78-29	11757-11767	algorithms	_
78-30	11768-11770	as	_
78-31	11771-11780	described	_
78-32	11781-11786	above	_
78-33	11787-11788	.	_

Text=The registered partial volume images were then modulated by dividing them with the Jacobian of the warp field to correct for local expansion or contraction.
79-1	11789-11792	The	_
79-2	11793-11803	registered	_
79-3	11804-11811	partial	_
79-4	11812-11818	volume	_
79-5	11819-11825	images	_
79-6	11826-11830	were	_
79-7	11831-11835	then	_
79-8	11836-11845	modulated	_
79-9	11846-11848	by	_
79-10	11849-11857	dividing	_
79-11	11858-11862	them	_
79-12	11863-11867	with	_
79-13	11868-11871	the	_
79-14	11872-11880	Jacobian	_
79-15	11881-11883	of	_
79-16	11884-11887	the	_
79-17	11888-11892	warp	_
79-18	11893-11898	field	_
79-19	11899-11901	to	_
79-20	11902-11909	correct	_
79-21	11910-11913	for	_
79-22	11914-11919	local	_
79-23	11920-11929	expansion	_
79-24	11930-11932	or	_
79-25	11933-11944	contraction	_
79-26	11945-11946	.	_

Text=The modulated segmented images, which represent the GMV, were then smoothed with an isotropic Gaussian kernel with a 3 mm standard deviation.
80-1	11947-11950	The	_
80-2	11951-11960	modulated	_
80-3	11961-11970	segmented	_
80-4	11971-11977	images	_
80-5	11978-11979	,	_
80-6	11980-11985	which	_
80-7	11986-11995	represent	_
80-8	11996-11999	the	_
80-9	12000-12003	GMV	_
80-10	12004-12005	,	_
80-11	12006-12010	were	_
80-12	12011-12015	then	_
80-13	12016-12024	smoothed	_
80-14	12025-12029	with	_
80-15	12030-12032	an	_
80-16	12033-12042	isotropic	_
80-17	12043-12051	Gaussian	_
80-18	12052-12058	kernel	_
80-19	12059-12063	with	_
80-20	12064-12065	a	_
80-21	12066-12067	3	_
80-22	12068-12070	mm	_
80-23	12071-12079	standard	_
80-24	12080-12089	deviation	_
80-25	12090-12091	.	_

Text=Finally, voxel-wise general linear models were used to examine correlations between brain data, group affiliation and years of abstinence.
81-1	12092-12099	Finally	_
81-2	12100-12101	,	_
81-3	12102-12112	voxel-wise	_
81-4	12113-12120	general	_
81-5	12121-12127	linear	_
81-6	12128-12134	models	_
81-7	12135-12139	were	_
81-8	12140-12144	used	_
81-9	12145-12147	to	_
81-10	12148-12155	examine	_
81-11	12156-12168	correlations	_
81-12	12169-12176	between	_
81-13	12177-12182	brain	_
81-14	12183-12187	data	_
81-15	12188-12189	,	_
81-16	12190-12195	group	_
81-17	12196-12207	affiliation	_
81-18	12208-12211	and	_
81-19	12212-12217	years	_
81-20	12218-12220	of	_
81-21	12221-12231	abstinence	_
81-22	12232-12233	.	_

Text=Non-parametric permutation methods (Randomise v2.1 in FSL) were used for inference on statistic maps.
82-1	12234-12248	Non-parametric	_
82-2	12249-12260	permutation	_
82-3	12261-12268	methods	_
82-4	12269-12270	(	_
82-5	12271-12280	Randomise	_
82-6	12281-12285	v2.1	_
82-7	12286-12288	in	_
82-8	12289-12292	FSL	_
82-9	12293-12294	)	_
82-10	12295-12299	were	_
82-11	12300-12304	used	_
82-12	12305-12308	for	_
82-13	12309-12318	inference	_
82-14	12319-12321	on	_
82-15	12322-12331	statistic	_
82-16	12332-12336	maps	_
82-17	12337-12338	.	_

Text=The null distribution at each voxel was constructed using 10,000 random permutations of the data.
83-1	12339-12342	The	_
83-2	12343-12347	null	_
83-3	12348-12360	distribution	_
83-4	12361-12363	at	_
83-5	12364-12368	each	_
83-6	12369-12374	voxel	_
83-7	12375-12378	was	_
83-8	12379-12390	constructed	_
83-9	12391-12396	using	_
83-10	12397-12403	10,000	_
83-11	12404-12410	random	_
83-12	12411-12423	permutations	_
83-13	12424-12426	of	_
83-14	12427-12430	the	_
83-15	12431-12435	data	_
83-16	12436-12437	.	_

Text=Threshold-free cluster enhancement (TFCE) was used to correct for multiple comparisons across the whole brain.
84-1	12438-12452	Threshold-free	_
84-2	12453-12460	cluster	_
84-3	12461-12472	enhancement	_
84-4	12473-12474	(	_
84-5	12475-12479	TFCE	_
84-6	12480-12481	)	_
84-7	12482-12485	was	_
84-8	12486-12490	used	_
84-9	12491-12493	to	_
84-10	12494-12501	correct	_
84-11	12502-12505	for	_
84-12	12506-12514	multiple	_
84-13	12515-12526	comparisons	_
84-14	12527-12533	across	_
84-15	12534-12537	the	_
84-16	12538-12543	whole	_
84-17	12544-12549	brain	_
84-18	12550-12551	.	_

Text=The mean GMV in each significant cluster was then extracted for each individual.
85-1	12552-12555	The	_
85-2	12556-12560	mean	_
85-3	12561-12564	GMV	_
85-4	12565-12567	in	_
85-5	12568-12572	each	_
85-6	12573-12584	significant	_
85-7	12585-12592	cluster	_
85-8	12593-12596	was	_
85-9	12597-12601	then	_
85-10	12602-12611	extracted	_
85-11	12612-12615	for	_
85-12	12616-12620	each	_
85-13	12621-12631	individual	_
85-14	12632-12633	.	_

Text=fMRI Analysis Functional MRI image preprocessing and statistical analyses were carried out using the FSL package (www.fmrib.ox.ac.uk/fsl).
86-1	12634-12638	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
86-2	12639-12647	Analysis	_
86-3	12648-12658	Functional	_
86-4	12659-12662	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
86-5	12663-12668	image	_
86-6	12669-12682	preprocessing	_
86-7	12683-12686	and	_
86-8	12687-12698	statistical	_
86-9	12699-12707	analyses	_
86-10	12708-12712	were	_
86-11	12713-12720	carried	_
86-12	12721-12724	out	_
86-13	12725-12730	using	_
86-14	12731-12734	the	_
86-15	12735-12738	FSL	_
86-16	12739-12746	package	_
86-17	12747-12748	(	_
86-18	12749-12771	www.fmrib.ox.ac.uk/fsl	_
86-19	12772-12773	)	_
86-20	12774-12775	.	_

Text=fMRI images were realigned to compensate for small residual head movements that were not captured by the PACE sequence.
87-1	12776-12780	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
87-2	12781-12787	images	_
87-3	12788-12792	were	_
87-4	12793-12802	realigned	_
87-5	12803-12805	to	_
87-6	12806-12816	compensate	_
87-7	12817-12820	for	_
87-8	12821-12826	small	_
87-9	12827-12835	residual	_
87-10	12836-12840	head	_
87-11	12841-12850	movements	_
87-12	12851-12855	that	_
87-13	12856-12860	were	_
87-14	12861-12864	not	_
87-15	12865-12873	captured	_
87-16	12874-12876	by	_
87-17	12877-12880	the	_
87-18	12881-12885	PACE	_
87-19	12886-12894	sequence	_
87-20	12895-12896	.	_

Text=Translational movement parameters never exceeded 1 voxel in any direction for any participant.
88-1	12897-12910	Translational	_
88-2	12911-12919	movement	_
88-3	12920-12930	parameters	_
88-4	12931-12936	never	_
88-5	12937-12945	exceeded	_
88-6	12946-12947	1	_
88-7	12948-12953	voxel	_
88-8	12954-12956	in	_
88-9	12957-12960	any	_
88-10	12961-12970	direction	_
88-11	12971-12974	for	_
88-12	12975-12978	any	_
88-13	12979-12990	participant	_
88-14	12991-12992	.	_

Text=Data were spatially smoothed using a 5-mm full-width-half-maximum (FWHM) Gaussian kernel.
89-1	12993-12997	Data	_
89-2	12998-13002	were	_
89-3	13003-13012	spatially	_
89-4	13013-13021	smoothed	_
89-5	13022-13027	using	_
89-6	13028-13029	a	_
89-7	13030-13034	5-mm	_
89-8	13035-13058	full-width-half-maximum	_
89-9	13059-13060	(	_
89-10	13061-13065	FWHM	_
89-11	13066-13067	)	_
89-12	13068-13076	Gaussian	_
89-13	13077-13083	kernel	_
89-14	13084-13085	.	_

Text=The data were filtered using a nonlinear high pass filter with a 100-second cut-off.
90-1	13086-13089	The	_
90-2	13090-13094	data	_
90-3	13095-13099	were	_
90-4	13100-13108	filtered	_
90-5	13109-13114	using	_
90-6	13115-13116	a	_
90-7	13117-13126	nonlinear	_
90-8	13127-13131	high	_
90-9	13132-13136	pass	_
90-10	13137-13143	filter	_
90-11	13144-13148	with	_
90-12	13149-13150	a	_
90-13	13151-13161	100-second	_
90-14	13162-13169	cut-off	_
90-15	13170-13171	.	_

Text=A two-step registration procedure was used whereby EPI images were first registered to the MPRAGE structural image, and then into standard MNI space, using affine transformations.
91-1	13172-13173	A	_
91-2	13174-13182	two-step	_
91-3	13183-13195	registration	_
91-4	13196-13205	procedure	_
91-5	13206-13209	was	_
91-6	13210-13214	used	_
91-7	13215-13222	whereby	_
91-8	13223-13226	EPI	_
91-9	13227-13233	images	_
91-10	13234-13238	were	_
91-11	13239-13244	first	_
91-12	13245-13255	registered	_
91-13	13256-13258	to	_
91-14	13259-13262	the	_
91-15	13263-13269	MPRAGE	_
91-16	13270-13280	structural	_
91-17	13281-13286	image	_
91-18	13287-13288	,	_
91-19	13289-13292	and	_
91-20	13293-13297	then	_
91-21	13298-13302	into	_
91-22	13303-13311	standard	_
91-23	13312-13315	MNI	_
91-24	13316-13321	space	_
91-25	13322-13323	,	_
91-26	13324-13329	using	_
91-27	13330-13336	affine	_
91-28	13337-13352	transformations	_
91-29	13353-13354	.	_

Text=Registration from MPRAGE structural image to standard space was further refined using FNIRT nonlinear registration.
92-1	13355-13367	Registration	_
92-2	13368-13372	from	_
92-3	13373-13379	MPRAGE	_
92-4	13380-13390	structural	_
92-5	13391-13396	image	_
92-6	13397-13399	to	_
92-7	13400-13408	standard	_
92-8	13409-13414	space	_
92-9	13415-13418	was	_
92-10	13419-13426	further	_
92-11	13427-13434	refined	_
92-12	13435-13440	using	_
92-13	13441-13446	FNIRT	_
92-14	13447-13456	nonlinear	_
92-15	13457-13469	registration	_
92-16	13470-13471	.	_

Text=Statistical analyses were performed in the native image space, with the statistical maps normalized to the standard space prior to higher-level analyses.
93-1	13472-13483	Statistical	_
93-2	13484-13492	analyses	_
93-3	13493-13497	were	_
93-4	13498-13507	performed	_
93-5	13508-13510	in	_
93-6	13511-13514	the	_
93-7	13515-13521	native	_
93-8	13522-13527	image	_
93-9	13528-13533	space	_
93-10	13534-13535	,	_
93-11	13536-13540	with	_
93-12	13541-13544	the	_
93-13	13545-13556	statistical	_
93-14	13557-13561	maps	_
93-15	13562-13572	normalized	_
93-16	13573-13575	to	_
93-17	13576-13579	the	_
93-18	13580-13588	standard	_
93-19	13589-13594	space	_
93-20	13595-13600	prior	_
93-21	13601-13603	to	_
93-22	13604-13616	higher-level	_
93-23	13617-13625	analyses	_
93-24	13626-13627	.	_

Text=The data were modeled at the first level using a general linear model (GLM) within FSL ’ s FILM module.
94-1	13628-13631	The	_
94-2	13632-13636	data	_
94-3	13637-13641	were	_
94-4	13642-13649	modeled	_
94-5	13650-13652	at	_
94-6	13653-13656	the	_
94-7	13657-13662	first	_
94-8	13663-13668	level	_
94-9	13669-13674	using	_
94-10	13675-13676	a	_
94-11	13677-13684	general	_
94-12	13685-13691	linear	_
94-13	13692-13697	model	_
94-14	13698-13699	(	_
94-15	13700-13703	GLM	_
94-16	13704-13705	)	_
94-17	13706-13712	within	_
94-18	13713-13716	FSL	_
94-19	13717-13718	’	_
94-20	13719-13720	s	_
94-21	13721-13725	FILM	_
94-22	13726-13732	module	_
94-23	13733-13734	.	_

Text=Brain activations for both cocaine-related pictures and natural scene pictures were modeled in the single subject level.
95-1	13735-13740	Brain	_
95-2	13741-13752	activations	_
95-3	13753-13756	for	_
95-4	13757-13761	both	_
95-5	13762-13777	cocaine-related	_
95-6	13778-13786	pictures	_
95-7	13787-13790	and	_
95-8	13791-13798	natural	_
95-9	13799-13804	scene	_
95-10	13805-13813	pictures	_
95-11	13814-13818	were	_
95-12	13819-13826	modeled	_
95-13	13827-13829	in	_
95-14	13830-13833	the	_
95-15	13834-13840	single	_
95-16	13841-13848	subject	_
95-17	13849-13854	level	_
95-18	13855-13856	.	_

Text=The boxcar response was convolved with the canonical hemodynamic response function (HRF, double-gamma) to generate regressors used in the GLM.
96-1	13857-13860	The	_
96-2	13861-13867	boxcar	_
96-3	13868-13876	response	_
96-4	13877-13880	was	_
96-5	13881-13890	convolved	_
96-6	13891-13895	with	_
96-7	13896-13899	the	_
96-8	13900-13909	canonical	_
96-9	13910-13921	hemodynamic	_
96-10	13922-13930	response	_
96-11	13931-13939	function	_
96-12	13940-13941	(	_
96-13	13942-13945	HRF	_
96-14	13946-13947	,	_
96-15	13948-13960	double-gamma	_
96-16	13961-13962	)	_
96-17	13963-13965	to	_
96-18	13966-13974	generate	_
96-19	13975-13985	regressors	_
96-20	13986-13990	used	_
96-21	13991-13993	in	_
96-22	13994-13997	the	_
96-23	13998-14001	GLM	_
96-24	14002-14003	.	_

Text=Temporal derivatives were included as covariates of no interest to improve statistical sensitivity.
97-1	14004-14012	Temporal	_
97-2	14013-14024	derivatives	_
97-3	14025-14029	were	_
97-4	14030-14038	included	_
97-5	14039-14041	as	_
97-6	14042-14052	covariates	_
97-7	14053-14055	of	_
97-8	14056-14058	no	_
97-9	14059-14067	interest	_
97-10	14068-14070	to	_
97-11	14071-14078	improve	_
97-12	14079-14090	statistical	_
97-13	14091-14102	sensitivity	_
97-14	14103-14104	.	_

Text=Resting periods were not explicitly modeled, and therefore constituted an implicit baseline.
98-1	14105-14112	Resting	_
98-2	14113-14120	periods	_
98-3	14121-14125	were	_
98-4	14126-14129	not	_
98-5	14130-14140	explicitly	_
98-6	14141-14148	modeled	_
98-7	14149-14150	,	_
98-8	14151-14154	and	_
98-9	14155-14164	therefore	_
98-10	14165-14176	constituted	_
98-11	14177-14179	an	_
98-12	14180-14188	implicit	_
98-13	14189-14197	baseline	_
98-14	14198-14199	.	_

Text=The six movement parameters were also included as covariates in the model.
99-1	14200-14203	The	_
99-2	14204-14207	six	_
99-3	14208-14216	movement	_
99-4	14217-14227	parameters	_
99-5	14228-14232	were	_
99-6	14233-14237	also	_
99-7	14238-14246	included	_
99-8	14247-14249	as	_
99-9	14250-14260	covariates	_
99-10	14261-14263	in	_
99-11	14264-14267	the	_
99-12	14268-14273	model	_
99-13	14274-14275	.	_

Text=Higher level random-effects models were tested for group analyses using FMRIB ’ s Local Analysis of Mixed Effect stage 1 only with automatic outlier detection.
100-1	14276-14282	Higher	_
100-2	14283-14288	level	_
100-3	14289-14303	random-effects	_
100-4	14304-14310	models	_
100-5	14311-14315	were	_
100-6	14316-14322	tested	_
100-7	14323-14326	for	_
100-8	14327-14332	group	_
100-9	14333-14341	analyses	_
100-10	14342-14347	using	_
100-11	14348-14353	FMRIB	_
100-12	14354-14355	’	_
100-13	14356-14357	s	_
100-14	14358-14363	Local	_
100-15	14364-14372	Analysis	_
100-16	14373-14375	of	_
100-17	14376-14381	Mixed	_
100-18	14382-14388	Effect	_
100-19	14389-14394	stage	_
100-20	14395-14396	1	_
100-21	14397-14401	only	_
100-22	14402-14406	with	_
100-23	14407-14416	automatic	_
100-24	14417-14424	outlier	_
100-25	14425-14434	detection	_
100-26	14435-14436	.	_

Text=Group images were evaluated with a height threshold of Z> 3 and a cluster probability of p <0.05, corrected for whole-brain multiple comparisons based on Gaussian random field theory.
101-1	14437-14442	Group	_
101-2	14443-14449	images	_
101-3	14450-14454	were	_
101-4	14455-14464	evaluated	_
101-5	14465-14469	with	_
101-6	14470-14471	a	_
101-7	14472-14478	height	_
101-8	14479-14488	threshold	_
101-9	14489-14491	of	_
101-10	14492-14493	Z	_
101-11	14494-14495	>	_
101-12	14496-14497	3	_
101-13	14498-14501	and	_
101-14	14502-14503	a	_
101-15	14504-14511	cluster	_
101-16	14512-14523	probability	_
101-17	14524-14526	of	_
101-18	14527-14528	p	_
101-19	14529-14530	<	_
101-20	14531-14535	0.05	_
101-21	14536-14537	,	_
101-22	14538-14547	corrected	_
101-23	14548-14551	for	_
101-24	14552-14563	whole-brain	_
101-25	14564-14572	multiple	_
101-26	14573-14584	comparisons	_
101-27	14585-14590	based	_
101-28	14591-14593	on	_
101-29	14594-14602	Gaussian	_
101-30	14603-14609	random	_
101-31	14610-14615	field	_
101-32	14616-14622	theory	_
101-33	14623-14624	.	_

Text=Regions of interests (ROI) were created from clusters of voxels with significant activation in the voxel-wise analyses.
102-1	14625-14632	Regions	_
102-2	14633-14635	of	_
102-3	14636-14645	interests	_
102-4	14646-14647	(	_
102-5	14648-14651	ROI	_
102-6	14652-14653	)	_
102-7	14654-14658	were	_
102-8	14659-14666	created	_
102-9	14667-14671	from	_
102-10	14672-14680	clusters	_
102-11	14681-14683	of	_
102-12	14684-14690	voxels	_
102-13	14691-14695	with	_
102-14	14696-14707	significant	_
102-15	14708-14718	activation	_
102-16	14719-14721	in	_
102-17	14722-14725	the	_
102-18	14726-14736	voxel-wise	_
102-19	14737-14745	analyses	_
102-20	14746-14747	.	_

Text=Analyses were performed by extracting parameter estimates (betas) of each type of stimuli from the fitted model and averaging across all voxels in the cluster for each participant.
103-1	14748-14756	Analyses	_
103-2	14757-14761	were	_
103-3	14762-14771	performed	_
103-4	14772-14774	by	_
103-5	14775-14785	extracting	_
103-6	14786-14795	parameter	_
103-7	14796-14805	estimates	_
103-8	14806-14807	(	_
103-9	14808-14813	betas	_
103-10	14814-14815	)	_
103-11	14816-14818	of	_
103-12	14819-14823	each	_
103-13	14824-14828	type	_
103-14	14829-14831	of	_
103-15	14832-14839	stimuli	_
103-16	14840-14844	from	_
103-17	14845-14848	the	_
103-18	14849-14855	fitted	_
103-19	14856-14861	model	_
103-20	14862-14865	and	_
103-21	14866-14875	averaging	_
103-22	14876-14882	across	_
103-23	14883-14886	all	_
103-24	14887-14893	voxels	_
103-25	14894-14896	in	_
103-26	14897-14900	the	_
103-27	14901-14908	cluster	_
103-28	14909-14912	for	_
103-29	14913-14917	each	_
103-30	14918-14929	participant	_
103-31	14930-14931	.	_

Text=Percent signal changes were calculated using a method suggested by Mumford (http: //mumford.fmripower.org/perchange_guide.pdf).
104-1	14932-14939	Percent	_
104-2	14940-14946	signal	_
104-3	14947-14954	changes	_
104-4	14955-14959	were	_
104-5	14960-14970	calculated	_
104-6	14971-14976	using	_
104-7	14977-14978	a	_
104-8	14979-14985	method	_
104-9	14986-14995	suggested	_
104-10	14996-14998	by	_
104-11	14999-15006	Mumford	_
104-12	15007-15008	(	_
104-13	15009-15013	http	_
104-14	15014-15015	:	_
104-15	15016-15059	//mumford.fmripower.org/perchange_guide.pdf	_
104-16	15060-15061	)	_
104-17	15062-15063	.	_

Text=Functional Connectivity Analysis To better understand key brain networks associated with long-term cocaine abstinence, the time courses of the following four seed regions revealed in the fMRI results were extracted: (1) the right striatum (MNI coordinates: 10, 14, 0); (2) the left insula (MNI coordinates: -40, 6, -10); (3) the right Lateral Frontal Pole (LFP; MNI coordinates: 24, 44, 42); (4) the left VMPFC (MNI coordinates: -14, 56, 14).
105-1	15064-15074	Functional	_
105-2	15075-15087	Connectivity	_
105-3	15088-15096	Analysis	_
105-4	15097-15099	To	_
105-5	15100-15106	better	_
105-6	15107-15117	understand	_
105-7	15118-15121	key	_
105-8	15122-15127	brain	_
105-9	15128-15136	networks	_
105-10	15137-15147	associated	_
105-11	15148-15152	with	_
105-12	15153-15162	long-term	_
105-13	15163-15170	cocaine	_
105-14	15171-15181	abstinence	_
105-15	15182-15183	,	_
105-16	15184-15187	the	_
105-17	15188-15192	time	_
105-18	15193-15200	courses	_
105-19	15201-15203	of	_
105-20	15204-15207	the	_
105-21	15208-15217	following	_
105-22	15218-15222	four	_
105-23	15223-15227	seed	_
105-24	15228-15235	regions	_
105-25	15236-15244	revealed	_
105-26	15245-15247	in	_
105-27	15248-15251	the	_
105-28	15252-15256	fMRI	_
105-29	15257-15264	results	_
105-30	15265-15269	were	_
105-31	15270-15279	extracted	_
105-32	15280-15281	:	_
105-33	15282-15283	(	_
105-34	15284-15285	1	_
105-35	15286-15287	)	_
105-36	15288-15291	the	_
105-37	15292-15297	right	_
105-38	15298-15306	striatum	_
105-39	15307-15308	(	_
105-40	15309-15312	MNI	_
105-41	15313-15324	coordinates	_
105-42	15325-15326	:	_
105-43	15327-15329	10	_
105-44	15330-15331	,	_
105-45	15332-15334	14	_
105-46	15335-15336	,	_
105-47	15337-15338	0	_
105-48	15339-15340	)	_
105-49	15341-15342	;	_
105-50	15343-15344	(	_
105-51	15345-15346	2	_
105-52	15347-15348	)	_
105-53	15349-15352	the	_
105-54	15353-15357	left	_
105-55	15358-15364	insula	_
105-56	15365-15366	(	_
105-57	15367-15370	MNI	_
105-58	15371-15382	coordinates	_
105-59	15383-15384	:	_
105-60	15385-15388	-40	_
105-61	15389-15390	,	_
105-62	15391-15392	6	_
105-63	15393-15394	,	_
105-64	15395-15398	-10	_
105-65	15399-15400	)	_
105-66	15401-15402	;	_
105-67	15403-15404	(	_
105-68	15405-15406	3	_
105-69	15407-15408	)	_
105-70	15409-15412	the	_
105-71	15413-15418	right	_
105-72	15419-15426	Lateral	_
105-73	15427-15434	Frontal	_
105-74	15435-15439	Pole	_
105-75	15440-15441	(	_
105-76	15442-15445	LFP	_
105-77	15446-15447	;	_
105-78	15448-15451	MNI	_
105-79	15452-15463	coordinates	_
105-80	15464-15465	:	_
105-81	15466-15468	24	_
105-82	15469-15470	,	_
105-83	15471-15473	44	_
105-84	15474-15475	,	_
105-85	15476-15478	42	_
105-86	15479-15480	)	_
105-87	15481-15482	;	_
105-88	15483-15484	(	_
105-89	15485-15486	4	_
105-90	15487-15488	)	_
105-91	15489-15492	the	_
105-92	15493-15497	left	_
105-93	15498-15503	VMPFC	_
105-94	15504-15505	(	_
105-95	15506-15509	MNI	_
105-96	15510-15521	coordinates	_
105-97	15522-15523	:	_
105-98	15524-15527	-14	_
105-99	15528-15529	,	_
105-100	15530-15532	56	_
105-101	15533-15534	,	_
105-102	15535-15537	14	_
105-103	15538-15539	)	_
105-104	15540-15541	.	_

Text=These ROIs were defined as 6 mm spheres centered on the MNI coordinates mentioned above.
106-1	15542-15547	These	_
106-2	15548-15552	ROIs	_
106-3	15553-15557	were	_
106-4	15558-15565	defined	_
106-5	15566-15568	as	_
106-6	15569-15570	6	_
106-7	15571-15573	mm	_
106-8	15574-15581	spheres	_
106-9	15582-15590	centered	_
106-10	15591-15593	on	_
106-11	15594-15597	the	_
106-12	15598-15601	MNI	_
106-13	15602-15613	coordinates	_
106-14	15614-15623	mentioned	_
106-15	15624-15629	above	_
106-16	15630-15631	.	_

Text=Pearson product-moment correlational analysis was performed between the time courses of each pair of ROIs for each subject separately.
107-1	15632-15639	Pearson	_
107-2	15640-15654	product-moment	_
107-3	15655-15668	correlational	_
107-4	15669-15677	analysis	_
107-5	15678-15681	was	_
107-6	15682-15691	performed	_
107-7	15692-15699	between	_
107-8	15700-15703	the	_
107-9	15704-15708	time	_
107-10	15709-15716	courses	_
107-11	15717-15719	of	_
107-12	15720-15724	each	_
107-13	15725-15729	pair	_
107-14	15730-15732	of	_
107-15	15733-15737	ROIs	_
107-16	15738-15741	for	_
107-17	15742-15746	each	_
107-18	15747-15754	subject	_
107-19	15755-15765	separately	_
107-20	15766-15767	.	_

Text=Between-group differences and correlations with years of abstinence were then assessed.
108-1	15768-15781	Between-group	_
108-2	15782-15793	differences	_
108-3	15794-15797	and	_
108-4	15798-15810	correlations	_
108-5	15811-15815	with	_
108-6	15816-15821	years	_
108-7	15822-15824	of	_
108-8	15825-15835	abstinence	_
108-9	15836-15840	were	_
108-10	15841-15845	then	_
108-11	15846-15854	assessed	_
108-12	15855-15856	.	_

